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Abstract: Background: 
Although the use of proliferation markers/profiles has been recommended 
when choosing the appropriate systemic-treatment, the best molecular-
marker/test that should be used needs to be identified.  Given that SPAG5 
has a fundamental role in mitotic-progression, and is associated with 
many features of proliferation, we hypothesized that SPAG5 could be a 
better indicator of proliferation activity, and provide a more accurate 
guide for the delivery of systemic therapies in breast cancer (BC). 
Subsequently we investigated the clinico-pathological utility of SPAG5: 
gene copy number aberrations (CNAs); mRNA and protein expression, in over 
10,000 BCs.  
Methods: 
To identify factors that drive proliferation and its associated features 
in BC an artificial neural network (ANN) based integrative data-mining 
methodology was applied to three cohorts [(Nottingham-discovery (ND), 
Uppsala and METABRIC (Molecular Taxonomy of Breast Cancer International 
Consortium)], Integrated analysis of SPAG5-gene CNAs, transcript and 
protein expression was further conducted in the ND cohort (n=171) and 
validated in the METABRIC cohort (n=1980). In addition, the associations 
of SPAG5 CNAs, transcript and/or protein with breast cancer specific 
survival (BCSS), disease free survival (DFS) and/or distant relapse free 
survival (DRFS) were analysed in multiple cohorts including Uppsala 
(n=249), METABRIC (n=1980), untreated lymph node negative cohorts 
(n=684), a combined multicentre clinical data set (n=5439), Nottingham 
historical early-stage-primary BC  (Nottingham-HES-BC; n=1650), 
Nottingham ER-negative BC (n=697), Nottingham anthracycline-Neoadjuvant-
chemotherapy (Nottingham-AC-Neo-ACT; n=200), and MD Anderson Cancer 
Centre Taxane/anthracycline (MDACC-T/AC-Neo-ACT; n=508) cohorts. The 
association of SPAG5 transcript and protein expression with pathological 
response rate (pCR) were also tested in [MDACC-T/AC-Neo-ACT (n=508) and 
the phase II trial NCT00455533; n=253)] and [Nottingham-AC-Neo-ACT 
(n=200)] cohorts; respectively.   
Findings: 
SPAG5 gene gain/amplification at the Ch17q11·2 locus was found in 10.4%; 
(206/1980) of all BCs and in 19·4% of PAM50-HER2 (46/237) and 17·8% of 
PAM50-LumB BC subclasses (87/488); METABRIC cohort. SPAG5-CNA 
gain/amplification and high SPAG5-transcript and SPAG5-protein (+) were 
associated with increased risk of death from BC [Uppsala; (HR (CI 95%): 
1·50 (1·18-1·92); p=0·00010, METABRIC; (HR (CI 95%): 1·68 (1·40-2·01) 
p<0·0001), and Nottingham-HSE-BC; (HR (CI 95%): 1·68 (1·32-2·12), 
p<0·0001); respectively]. Multivariable Cox regression models, including 
other validated-prognostic factors, showed that SPAG5-transcript+ and 
SPAG5-protein+ were associated with shorter BCSS [Uppsala: (HR (CI 95%): 
1·62 (1·03-2·53) p=0·036); METABRIC: (HR (CI 95%): 1·27 (1·02-1·58) 
p=0·034); untreated LN- cohort: (HR (CI 95%): 2·34 (1·24-4·42) p=0·0090), 
and Nottingham-HES-BC (HR (CI 95%): 1·73 (1·23-2·46) p=0·0020); 
respectively].  
In ER-negative-BC with SPAG5-protein+, administration of anthracycline-
adjuvant-chemotherapy had reduced the risk of death by 60% compared to 
chemotherapy-naive (HR (95% CI): 0·37 (0·20-0·60); p=0·0010).  A 
multivariable Cox regression analysis, which included other validated 
prognostic factors for chemotherapy, revealed that SPAG5-transcript+ was 
independently associated with decreased risk of DRFS after receiving 
Taxane/anthracycline-Neo-ACT [MDACC-T/AC-Neo-ACT: (HR (CI 95%): 0·68 
(0·48-0·97); p=0·0070)]. 
In multivariable logistic regression analysis, both SPAG5-transcript+ and 
SPAG5-protein+ and were independent predictors for higher pCR after 
combination-cytotoxic chemotherapy [MDACC-T/AC-Neo-ACT: (OR (95% CI) 1·71 
(1·07-2·74); p=0·024), and Nottingham-AC-Neo-AC: (OR (95% CI): 8·75 
(2·42-31); p=0·0010); respectively].  
Interpretation:    
SPAG5 is a novel amplified gene on Ch17q11.2 in PAM50-LumB and PAM-HER2 
BC, and its transcript and protein products are independent prognostic 
and predictive biomarkers, with potential clinical utility as a biomarker 
for combination cytotoxic chemotherapy sensitivity, especially in ER-
negative BC.   
Funding: 
Nottingham Hospitals Charity and the John and Lucille van Geest 
Foundation.  
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Research in context 
Evidence before this study 
There is an urgent need to find a novel biomarker that is associated with proliferation 
features in breast cancer and could potentially be used as a prognostic and/or 
predictive biomarker.  A non-linear artificial neural network (ANN) modelling based 
data mining approach and network-inference algorithm was implemented for multiple 
proliferation related targets across three breast cancer gene expression datasets to 
ascertain factors that could drive proliferation. The integrated findings identified 
SPAG5 featuring prominently in the interactome map and greatly impacting BC 
patient survival.  A PubMed search using the term “SPAG5” for publications up to 1st 
May 2012 retrieved 30 articles, only two of which reported on the overexpression of 
SPAG5 mRNA and clinical outcome in cancer. These reported on a small set of 
breast and lung cancers.  The majority of the articles studied the biological function 
of SPAG5 in cell cycle progression, thereby providing evidence for its fundamental 
role in the function and dynamic regulation of mitotic spindles, mitotic progression, 
and the fidelity of chromosome segregation.  
Added value of this study 
To the best of our knowledge this is the first multi-dimensional study, with more than 
10,000 patients, to report on the clinicopathological utilities of SPAG5 in breast 
cancer. Our findings suggest that: 1) Amplification/gain of the SPAG5 locus at 
Ch17q11·2 occurs in 10-20% of all breast cancers; 2) The SPAG5-gene copy 
number aberrations (CNAs) and its transcript and protein are associated with poor 
clinical outcome and adverse clinicopathological features, including TP53-mutation, 
PAM50-LumB, and PAM50-HER2; and 3) Both high expression of SPAG5 mRNA 
transcript and protein are independent predictors for response to chemotherapy.  
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Implications of all the available evidence 
Our findings have the potential to introduce an accurate predictive biomarker for 
chemotherapy response, which would facilitate the tailoring of treatments to 
individual patients with breast cancer. This work may lead to the development of 
novel strategies for more effectively managing and treating a subtype of breast 
cancer.  
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Abstract  
Background: 
Although the use of proliferation markers/profiles has been recommended when 
choosing the appropriate systemic-treatment, the best molecular-marker/test that 
should be used needs to be identified.  Given that SPAG5 has a fundamental role in 
mitotic-progression, and is associated with many features of proliferation, we 
hypothesized that SPAG5 could be a better indicator of proliferation activity, and 
provide a more accurate guide for the delivery of systemic therapies in breast cancer 
(BC). Subsequently we investigated the clinico-pathological utility of SPAG5: gene 
copy number aberrations (CNAs); mRNA and protein expression, in over 10,000 
BCs.  
Methods: 
To identify factors that drive proliferation and its associated features in BC an 
artificial neural network (ANN) based integrative data-mining methodology was 
applied to three cohorts [(Nottingham-discovery (ND), Uppsala and METABRIC 
(Molecular Taxonomy of Breast Cancer International Consortium)], Integrated 
analysis of SPAG5-gene CNAs, transcript and protein expression was further 
conducted in the ND cohort (n=171) and validated in the METABRIC cohort 
(n=1980). In addition, the associations of SPAG5 CNAs, transcript and/or protein 
with breast cancer specific survival (BCSS), disease free survival (DFS) and/or 
distant relapse free survival (DRFS) were analysed in multiple cohorts including 
Uppsala (n=249), METABRIC (n=1980), untreated lymph node negative cohorts 
(n=684), a combined multicentre clinical data set (n=5439), Nottingham historical 
early-stage-primary BC  (Nottingham-HES-BC; n=1650), Nottingham ER-negative 
BC (n=697), Nottingham anthracycline-Neoadjuvant-chemotherapy (Nottingham-AC-
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Neo-ACT; n=200), and MD Anderson Cancer Centre Taxane/anthracycline 
(MDACC-T/AC-Neo-ACT; n=508) cohorts. The association of SPAG5 transcript and 
protein expression with pathological response rate (pCR) were also tested in 
[MDACC-T/AC-Neo-ACT (n=508) and the phase II trial NCT00455533; n=253)] and 
[Nottingham-AC-Neo-ACT (n=200)] cohorts; respectively.   
Findings: 
SPAG5 gene gain/amplification at the Ch17q11·2 locus was found in 10.4%; 
(206/1980) of all BCs and in 19·4% of PAM50-HER2 (46/237) and 17·8% of PAM50-
LumB BC subclasses (87/488); METABRIC cohort. SPAG5-CNA gain/amplification 
and high SPAG5-transcript and SPAG5-protein  were associated with increased risk 
of death from BC [Uppsala; (HR (CI 95%): 1·50 (1·18-1·92); p=0·00010, METABRIC; 
(HR (CI 95%): 1·68 (1·40-2·01) p<0·0001), and Nottingham-HSE-BC; (HR (CI 95%): 
1·68 (1·32-2·12), p<0·0001); respectively]. Multivariable Cox regression models, 
including other validated-prognostic factors, showed that SPAG5-transcript+ and 
SPAG5-protein+ were associated with shorter BCSS [Uppsala: (HR (CI 95%): 1·62 
(1·03-2·53) p=0·036); METABRIC: (HR (CI 95%): 1·27 (1·02-1·58) p=0·034); 
untreated LN-negative cohort: (HR (CI 95%): 2·34 (1·24-4·42) p=0·0090), and 
Nottingham-HES-BC (HR (CI 95%): 1·73 (1·23-2·46) p=0·0020); respectively].  
In ER-negative-BC with SPAG5-protein+, administration of anthracycline-adjuvant-
chemotherapy had reduced the risk of death by 63% compared to chemotherapy-
naive (HR (95% CI): 0·37 (0·20-0·60); p=0·0010).  A multivariable Cox regression 
analysis, which included other validated prognostic factors for chemotherapy, 
revealed that SPAG5-transcript+ was independently associated with decreased risk 
of DRFS after receiving Taxane/anthracycline-Neo-ACT [MDACC-T/AC-Neo-ACT: 
(HR (CI 95%): 0·68 (0·48-0·97); p=0·0070)]. 
8 
 
In multivariable logistic regression analysis, both SPAG5-transcript+ and SPAG5-
protein+ and were independent predictors for higher pCR after combination-cytotoxic 
chemotherapy [MDACC-T/AC-Neo-ACT: (OR (95% CI) 1·71 (1·07-2·74); p=0·024), 
and Nottingham-AC-Neo-AC: (OR (95% CI): 8·75 (2·42-31); p=0·0010); 
respectively].  
Interpretation:    
SPAG5 is a novel amplified gene on Ch17q11.2 in PAM50-LumB and PAM-HER2 
BC, and its transcript and protein products are independent prognostic and predictive 
biomarkers, with potential clinical utility as a biomarker for combination cytotoxic 
chemotherapy sensitivity, especially in ER-negative BC.   
Funding: 
Nottingham Hospitals Charity and the John and Lucille van Geest Foundation.   
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Words=3000 
Introduction 
Approximately 1·68 million women are diagnosed with BC worldwide annually, with 
over 500,000 dying of the disease (~1,400 per day).1  Despite continuing success, 
the delivery of effective precision medicine requires: 1) the discovery of novel 
therapeutic targets in subgroups of BC, and 2) improvements in the efficacy  of 
treatments by identifying stratification biomarkers that can predict an individual 
patient’s response to a particular therapy.2 Although chemotherapy is offered to 
approximately 60% of patients with BC,3 either alone or in combination with other 
targeted-therapies, a meta-analysis of 123 randomized trials involving over 100,000 
patients has concluded that chemotherapy reduces recurrence and mortality rates by 
only 20-33%.4  Although a St Gallen International Expert Consensus recently 
recommended the use of proliferation markers/profiles when choosing the 
appropriate systemic-treatment, the best molecular-marker/test that should be used 
continues to be debated.5 
The main aim of the current study was to identify a biomarker that could drive 
proliferation and could be used to stratify BC patients’ outcome. To achieve this, we 
decided to apply an artificial neural network (ANN) algorithm 6 to three gene 
expression datasets, and use factors that are directly and indirectly related to 
proliferation, defined as clinical class questions, to train it. The most prominent 
genes in the resulting interactome-map would then be developed and the best 
followed up, through an integrated analysis at the levels of copy number aberrations 
(CNAs), mRNA transcript and protein, in order to assess the clinico-pathological 
implications and utilities in a combined total of over 10,000 patients. Here we present 
10 
 
the results of our ANN analysis, and the gene SPAG5 (Sperm-associated antigen 5), 
which featured prominently in the interactome -map of proliferation and had a great 
impact on patients’ survival.   Given that SPAG5 has a fundamental role in the 
function and dynamic regulation of mitotic spindles, and in mitotic progression and 
chromosome segregation fidelity, 7 we hypothesized that SPAG5 could be a better 
measurement of proliferation activity and provide a more accurate guide for the 
delivery of systemic therapies in BC.  
Patients and Methods  
Study design and cohorts 
Study design, patient’s cohorts and demographics used in this study are summarized 
in Fig.1 and appendix p1-3. 
All patients completed written informed consented, as per hospital standard of care, 
for excess tumour tissue to be used in research. The study was approved by the 
Institutional Review Board or Independent Ethics Committee and the Hospital 
Research and Innovations Department at all participating sites. Tumour Marker 
Prognostic Studies (REMARK) criteria, as recommended by McShane et al, 8 were 
followed throughout this study.  
I) Identification of proliferation drivers and validation the prognostic function 
of SPAG5-CNAs, transcript and protein expression in BC 
A) Discovery cohort: Nottingham discovery (ND) cohort (n=171) 
The ANN modelling-based data mining approach to identify factors that drive 
proliferation and its associated features in BC was explored in the ND cohort, 
consisting of a set of 171 stage I and II invasive BC with a median follow-up of 180 
11 
 
months   (IQR 143-194), previously described by our group in several molecular 
profiling studies.9 This cohort has also been used for exploring the integrated 
analysis of SPAG5 CNAs, transcript, and protein expression.  
B) Test cohort: Uppsala (n=249)  
The ANN modelling-based data mining approach and the clinicopathological 
significance of SPAG5 gene expression were tested in the Uppsala cohort 
composed of 315 women representing 65% of all BCs resected in Uppsala County, 
Sweden (1987-1989) with a median follow-up of 126 months   (IQR 119-134).  Gene 
expression data were available for only 249 patients. 10 
C) Validation cohorts: 
1) METABRIC (Molecular Taxonomy of Breast Cancer International 
Consortium) cohort (n=1980)  
The ANN modelling-based data mining approach and integrated SPAG5-CNA and 
SPAG5-trancript analysis was validated using the METABRIC cohort; a set of 1980 
BCs with median follow-up 109 months (IQR 62-155).11   In this cohort, oestrogen 
receptor positive (ER-positive) and/or lymph-node negative (LN-negative) patients 
did not receive adjuvant chemotherapy, whereas ER negative and/or lymph-node 
positive (LN-positive) patients received adjuvant chemotherapy. Additionally, none of 
the human epidermal growth factor receptor-2 (HER2) overexpression patients 
received trastuzumab. 
2) Untreated lymph-node negative BC cohorts:  
The prognostic significance of SPAG5-mRNA expression was assessed in three 
publically available datasets of LN-negative BC (n=684). These patients did not 
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receive any adjuvant systemic therapy, thereby allowing the effect of SPAG5-
transcript on the natural history of the disease to be observed. These datasets were 
described in previous publications by Wang et al 12 (n=286), Desmedt et al 13 
(n=196), and Schmidt et al 14 (n=200).  The median follow up of each cohort is 
summarized in appendix p1-3.  
3) Multi-Centre Combined cohorts (MCC; n=5439) 
We evaluated the prognostic utility of SPAG5-mRNA expression in a large combined 
BC cohort which was sourced from 36 publically-available, global datasets (n=5439) 
using the online bc-GenExMiner program (http://bcgenex.centregauducheau.fr). 15   
A list of all the datasets, with references, is summarized in appendix p4-6. 
4) Nottingham Historical early stage BC cohort (Nottingham-HES-BC; n=1650)  
The clinicopathological significance and prognosis of SPAG5 protein expression was 
also validated in a cohort of BC (n=1650; age>71 years) 16 whose tissues were 
suitable for SPAG5 immunohistochemistry (IHC). These patients were diagnosed 
and treated uniformly between 1986 and 1999 at the Nottingham City Hospital 
(NCH), Nottingham, UK. Patients within the good prognosis group (Nottingham 
Prognostic Index (NPI) <3·4) did not receive systemic adjuvant therapy. Pre-
menopausal patients within the moderate and poor prognosis groups were 
candidates for CMF chemotherapy (cyclophosphamide 750 mg m−2, methotrexate 50 
mg m−2 and 5-fluorouracil 1 g m−2, on day 1 of a 21-day cycle.). Conversely, 
postmenopausal ER-positive patients with moderate or poor NPI were offered 
hormonal therapy, whereas ER-negative patients received CMF chemotherapy. 
Clinical data were maintained on a prospective basis with a median follow-up of 143 
months   (IQR 114-174). 16.  The median follow up of subgroups is summarized in 
appendix p1-3. 
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II) The clinical significance of SPAG5-protein and SPAG5-transcript expression 
in the context of currently used chemotherapy in BC  
In order to evaluate the value of SPAG5 transcript and protein expression as a 
biomarker in the context of current combination cytotoxic chemotherapy, we further 
evaluated the clinical significance of SPAG5 protein and transcript expression in 
adjuvant and neo-adjuvant chemotherapy settings.  
1. Nottingham early stage ER-negative BC adjuvant chemotherapy cohort 
(Nottingham-ER-negative ; n=697) 
To evaluate the survival benefit of SPAG5-protein expression, we analysed its 
expression in a consecutive series of 697 early stage ER-negative BC’s who had 
been diagnosed and managed at NCH between 1999 and 2007.  This series 
included: 1) The ER-negative BC patients of Nottingham historical early stage BC 
cohort (n=332) who were managed before 2000 and treated with either no 
chemotherapy or adjuvant CMF, and 2) the new ER-negative early stage BC patients 
(n=365) who were managed after 2000 and received either no chemotherapy or 
anthracycline-based adjuvant chemotherapy (AC-ACT). 17 The median follow up of 
different treatment subgroups is summarized in appendix p1-3. 
2. Nottingham anthracycline based Neo-Adjuvant Chemotherapy cohort 
(Nottingham AC-Neo-ACT; n=200) 
The relationship between SPAG5-protein expression and response to chemotherapy 
was evaluated by investigating its expression in pair-matched pre-chemotherapy 
core biopsies and post-chemotherapy surgical specimens, from 200 female patients 
with locally-advanced primary BC (LAP-BC) (stage IIIA-C) that had been treated with 
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anthracycline-based Neo-ACT (AC-Neo-ACT) 18 at NCH between 1996 and 2012.  
Sixty three percent of patients (127/200) received six cycles of an anthracycline-
based therapy (FEC: 5-fluorouracil (5-FU) 500 mg m−2, epirubicin 75–100 mg m−2, 
cyclophosphamide 500 mg m−2, on day 1 of a 21 day cycle), whereas 37% of 
patients received FEC plus Taxane (73/200). All patients underwent mastectomy or 
breast-conserving surgery and axillary dissection, followed by adjuvant radiation 
therapy. Patients with ER-positive BCs were offered 5 years of adjuvant endocrine 
therapy.  The median follow-up time was 67 months (IRQ 27-81). 
University of Texas MD Anderson Cancer Centre-Taxane/Anthracycline-based 
neo-adjuvant chemotherapy cohort (MDACC-T/AC-Neo-ACT; n=508) 
The relationship between SPAG5-transcript expression and response to 
chemotherapy was evaluated using MDACC-T/AC-Neo-ACT cohort in which patients 
were selected for newly diagnosed ERBB2 (HER2- or HER2/neu) negative BC and 
treated with sequential taxane and anthracycline–based neo-adjuvant chemotherapy 
(then endocrine adjuvant therapy if ER-positive). Details of patients’ characteristics 
have been previously reported. 19 The median follow-up time was 38 months (IRQ 
26-53). 
3. Multicentre phase II AC-Neo-ACT clinical trial cohort (NCT00455533; 
n=253) 
The relationship between SPAG5-transcript and the response to AC-Neo-ACT was 
validated using a randomised, open-label, multicentre, phase II clinical trial 
(NCT00455533) in which women with early stage BC (T2–3, N0–3, M0, tumour size 
2·0 cm) have received AC-Neo-ACT regimens (cyclophosphamide plus doxorubicin 
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(AC), followed by ixabepilone or paclitaxel).  Full details of the study design and the 
patient characteristics have been described previously. 20 Out of 295 patients 
enrolled into the trial, 253 patients had available gene expression and pCR data.  
Procedures 
1- The ANN modelling-based data mining approach  
To identify factors that could drive proliferation and its associated features in BC, a 
number of factors that are directly and indirectly related to proliferation, defined as 
clinical class questions (e.g. histological-grade; mitotic index (MI); Ki67; TOP2A; 
KIF2C; BIRC5 and 5-year-survival), were analysed by applying an ANN modelling-
based data mining approach in three gene expression array transcriptomic datasets, 
that included the ND, Uppsala and METABRIC cohorts.  The ANNs have been 
selected to data mine the clinical data sets identified in this study as they have 
previously been shown to be able to identify biomarkers, with high sensitivity and 
specificity that predict clinical features with excellent validity for unseen data sets. 6 
In additions, ANNs unlike conventional statistical approaches (such as hierarchical 
clustering, principal components analysis or linear regression) are not limited by 
linear functionality; this provides improved representation of biological features. The 
ranked orders of genes, produced in this way were compared across multiple 
proliferation related clinical class questions within a given dataset. The top 100 
ranked genes for predicting each clinical class question, based on minimum average 
route mean squared error, were compared and commonalities identified at the probe 
level. Further comparisons were then made for the same clinical class questions in 
the other datasets in order to determine a consensus list of gene probes across all of 
the features and data sets.  The strongest 100 integrated interactions were selected 
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for visualisation in Cytoscape (Version 3.1.1, The Cytoscape Consortium; San-
Francisco, USA. 21   Further details of the ANN approach is presented in appendix 
p7-10.  
2- SPAG5 CNAs 
CNAs at the SPAG5 locus on chromosome 17q11.2 were retrieved from both high 
resolution (<100 kb) oligonucleotide microarrays, comparative genomic hybridization 
(aCGH; ND cohort), and Affymetrix SNP 6.0 platform profiling (METBRIC cohort) that 
has been previously described by our group. 9, 11 The oligonucleotide array data can 
be access at (http://www.ncbi.nlm.nih.gov/geo/; series accession number-GSE8757) 
whereas SNP data are available through the European Genotype Archive 
(http://www.ebi.ac.uk/ega/page.php) under accession Number: EGAS00000000082). 
An additional analysis considered a set of 85 individuals of European ancestry for 
whom genotyping was performed on non-cancerous tissue and gene expression 
values from matched normal tissue were available. 11 
3- SPAG5 and MKi67 gene expression 
SPAG5 and MKi67 mRNA expression data were retrieved and analysed in the 
following cohorts:- ND [using Agilent gene expression arrays at 
(http://www.ebi.ac.uk/miamexpress/ with accession number E-TABM-576), Uppsala 
[using Affymetrix U133A&B Gene-Chips microarray profiling data at 
(http://www.ncbi.nlm.nih.gov/geo/) with series accession number (GSE4922)], and 
METABRIC [using Illumina HT-12 v3 platform (Bead Arrays) 11 data at 
(http://www.ebi.ac.uk/ega/page.php) under accession Number 
(EGAS00000000082)].    In addition, the SPAG5 and MKi67 mRNA expression data 
has been retrieved for three publically available datasets of LN-negative BC  in which 
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patients did not receive any adjuvant systemic therapy: Wang et al12 (accession 
number: GSE2034; n=286), Desmedt et al13 (accession number: GSE7390; n=196), 
and Schmidt et al14 (accession number: GSE11121; n=200).  For the MCC cohort, 
details of the gene expression data processing, normalization and the statistical tests 
have been described previously. 15 In this cohort, gene expression data  were 
converted to a common scale (median equal to 0 and standard deviation equal to 1) 
in order to merge all of the studies data and create combined cohorts (for more 
details see appendix p8). 22 The gene expression data for the MDACC-T/AC-Neo-
ACT cohort and the phase II clinical trial (NCT00455533) has been downloaded 
using accession number GSE25066 and GSE41998; respectively. 
4- Immunohistochemistry (IHC) staining of SPAG5 and Ki67  
The ND, Nottingham-HES-BC, Nottingham-ER-negative and Nottingham-AC-Neo-
ACT cohorts were IHC profiled for SPAG5, Ki67 and other biological parameters.  
Tissue microarrays (TMAs), as described in detail in appendix p8-12 have been used 
for IHC profiling of SPAG5 in all cohorts except in Nottingham-AC-Neo-ACT where 
full-face sections of core biopsies have been used.    
Determination of the cut-offs 
The median in each cohort was used as cut-off between low and high expression 
gene/protein expression 
Outcomes: 
The clinicopathological and biomarkers associations: The clinicopathological 
and molecular characteristics of SPAG5 transcript were determined in the Uppsala, 
METABRIC, MCC and MDACC-T/AC-Neo-ACT cohorts.  SPAG5–CNA 
molecular/pathological associations were analysed in METABRIC cohort. The 
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associations between SPAG5 protein expression and clinicopathological parameters, 
as well as prognostic biomarkers, were analysed in the Nottingham-HES-BC, the 
Nottingham-ER-negative and the Nottingham-AC-Neo-ACT cohorts. The 
clinicopathological parameters including mainly: tumour size, lymph node stage, 
histological grade, genomic grade index (GGI), TP53 mutation, intrinsic molecular 
subclasses, PAM50, HER2 amplification/overexpression, hormone receptors, Ki67, 
mitotic index, Bcl2 and other biological biomarkers.   
Breast cancer specific survival (BCSS): SPAG5 transcript expression association 
with BCSS was explored in the ND cohort and validated in Uppsala, METABRIC and 
the untreated LN-negative Desmedt et al cohorts.  SPAG5-CNAs association with 
BCSS was tested in METABRIC cohort whereas the association between SPAG5 
protein expression and BCSS was analysed in the ND cohort, Nottingham-HES-BC 
cohort and Nottingham-ER-negative cohorts.   
Disease free survival (DFS): SPAG5 transcript expression association with DFS 
was examined in untreated LN-negative cohorts (Wang et al and Desmedt et al), 
MCC and Nottingham-AC-Neo-ACT cohorts.   
Distant relapse free survival (DRFS):  SPAG5 transcript expression association 
with DRFS was determined in untreated LN-negative Schmidt et al and Desmedt et 
al cohorts.  Furthermore, to test SPAG5 transcript expression as a biomarker for 
outcome after neo-adjuvant combination cytotoxic chemotherapy, the association 
with DRFS has been analysed in the MDACC-T/AC-Neo-ACT cohort.  
Pathological complete response (pCR) and residual cancer burden (RCB): To 
evaluate SPAG5 protein and transcript expression as a predictive biomarker for 
response to combination cytotoxic chemotherapy, the association with both pCR and 
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RCB 23 have been analysed in the Nottingham-AC-Neo-ACT,  the MDACC-T/AC-
Neo-ACT, and the phase II AC-Neo-ACT clinical trial cohort (NCT00455533); 
respectively. The pCR was defined as the absence of any residual invasive 
carcinoma at both the primary site and in axillary LNs. 
Statistical analysis were performed using STATISTICA (Stat Soft Ltd, Tulsa, USA) 
and SPSS (version 17, Chicago, USA) by the authors (TAF, GRB) who were blinded 
to the clinical data. The Chi-square test was used for testing associations between 
categorical variables, and a multivariable Cox model was fitted to the data using 
survival time as the endpoint.  All tests were two-sided with a 95% CI and a p value 
of <0·05 was considered to be indicative of statistical significance. Multiple-testing 
correction was applied to all p-values using the Bonferroni method. The range of 
corrections were (5 - 48,803) across the different analyses.  Gene-dosage levels to 
gene expression were evaluated using the Jonckheere's trend test in order to 
evaluate the significance of the correlation between CNAs and aberrant gene-
expression. Pearson correlations between mRNA expression log intensity values 
and SPAG5 protein expression (H-score) were used to determine whether mRNA 
expression levels correlated with protein levels. See appendix p8-9 for details. 
Power analysis and false discovery correction 
Power analysis for the ANN model was conducted using a logistic regression power 
model (of which ANNs are an extension with a greater power), using G*Power 3.1.9 
software (Heinrich Heine University of Dusseldorf, Dusseldorf, Germany). 24 To 
determine sample size, an alpha of 0·05, a power of 0·80, an effect size (odd ratio = 
1·72) and two-tailed test, were chosen for binary questions or classes (e.g., low vs., 
high expression).  Based on the assumptions of the power model, the desired 
20 
 
sample size is 88 (44 in each low and high class). The use of a Monti Carlo cross 
validation (MCCV) strategy was further used to prevent false discovery, over-fitting 
and to increase the power of the algorithm used (see appendix p7 for detail). By 
repeatedly testing on an unseen data set and stopping accordingly, over-fitting is 
prevented. False discovery is further reduced in this study by parallel analysis on 
multiple questions in multiple datasets.  With each separate analysis reducing the 
probability that a gene could be discovered by random chance, and yet still be a 
common result across multiple analyses, of separate datasets.  
The probability (p) of the 30 genes occurring as common in the top 100 out of the 
whole expression array for the three cohorts for a minimum of 4 proliferation-related 
factors = 1·43x10-31 (see the calculation in appendix p7).   
A retrospective power analysis was conducted to determine the confidence in the 
calculated hazard ratio and associated p value for 10 year survival and to ascertain 
how applicable the result would be to a global population.   
Results 
Our ANN analysis in three cohorts (ND, Uppsala and METABRIC cohorts) identified 
the top 100 ranked genes that predict most of the proliferation-related features 
(appendix p13-27). We chose to further study the clinicopathological implication of 
SPAG5 because it was found to be among 30 common gene-probes that were 
predictive across most of the proliferation features and datasets, and it features 
prominently in the interactome maps (appendix p25-27).  In addition, in a small set of 
BC, investigators found that SPAG5 transcript was a mong few genes that were 
associated with poor prognosis in ER-positive BC. 25   Because Ki67 has been used 
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by many investigators as a marker for proliferation when choosing the appropriate 
systemic-treatment, subsequently we chose to be used it as a control in our study.   
Gain/amplification at the SPAG5 locus (17q11·2) occurred in 16% (26/171) and 
10·4% (206/1980) of BC, in the ND and METABRIC cohorts respectively. SPAG5-
gain/amplification was more common in high-grade, PAM50-HER2, and PAM50-
LumB.  A strong correlation between SPAG5-CNA and SPAG5-transcript expression 
was apparent (ND cohort: Spearman-correlation r=0·81; Bonferroni-adjusted-
p=0·010) and METABRIC: Spearman-correlation r=0·87; Bonferroni-adjusted-
p<0·0001). ER-negative and ER-positive BC exhibited a higher level of SPAG5-
transcript (correlation-coefficient=0·19; Bonferroni-adjusted-p<0·0001 and 
correlation-coefficient=0·37; Bonferroni-adjusted-p<0·0001; respectively) compared 
to normal individuals. However, the level of SPAG5-transcripts in ER-negative 
disease was higher than that in ER-positive disease (correlation-coefficient=0·18; 
Bonferroni-adjusted-p<0·0001). Furthermore, the PAM50-LumB, PAM50-Basal and 
PAM50-HER2 BC-subclasses exhibited higher levels of SPAG5-transcripts than 
PAM-50-normal-like, PAM50-Lum-A disease, and normal tissue (all-adjusted-
p<0·0001; Figure appendix p28).   
As a continuous and categorical variable, compared to low SPAG5-transcript 
expression, high SPAG5-transcript level (>median) was associated with high-grade 
TP53- mutation, and HER2 gain/amplification. In the METABRIC study, 10-novel-
prognostic biological subgroups have been identified by the joint clustering of CNA 
and gene expression data (integrative-clusters (intClust)). 11 Herein, SPAG5-
gain/amplification was shown to be associated with intClust-1, 5, and 6 (all-
p<0·0001) whereas SPAG5-overexpression was associated with intClust-1, 5, 9, and 
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10; appendix p29-32. Furthermore, high SPAG5-transcript expression (>median) 
was associated with other molecular parameter/indices/subclasses that predict 
higher probability of response to Neo-ACT: RCB-0/I, 23 genomic-chemo-sensitivity 
predictor, 19  genomic-excellent-pathologic-response predictor, 19 96-gene-genomic-
grade index (GGI), 26 diagonal linear discrimination analysis of 30-gene  signature 
(DLDA30), 27 and PAM-50-gene signature 28 (all p<0·0001, appendix p33). 
Additionally, there was a strong correlation between SPAG5-transcript and SPAG5-
protein expression (Pearson-correlation (r=0·75); Bonferroni-adjusted-p=0·001).  In 
the Nottingham-HES-BC cohort, 20% (272/1368) of patients showed high SPAG5-
protein (H-score≥10) that was associated with aggressive phenotypes including 
HER2-overexpression (p=0·030), Luminal-B (ER-positive/HER-negative/high-Ki67), 
an absence of hormone receptors, and TP53-mutation (appendix p34-37). In the 
Nottingham-ER-negative cohort, high SPAG5-protein (H-score>10) was observed in 
51% (355/697) and was associated with lympho-vascular-invasion, high-grade, and 
high-ki67 (all p<0·0001; appendix p38-41). In Nottingham AC-Neo-ACT locally 
advanced BC cohort, high SPAG5-protein (H-score>10) was observed in 25·0% 
(50/200) of pre-chemotherapy core biopsies and was associated with high-grade, 
Luminal-B (ER-positive/HER2-negative/high Ki67), ER-negative/HER-negative, and 
TP53-mutation (all adjusted p<0·0001). Among different cohorts neither SPAG5 
transcript nor protein was associated with LN-stage or disease clinical stage.  
SPAG5-gain/amplification was associated with shorter BCSS than SPAG5-
normal/loss in all patients (HR (CI 95%):1·50 (1·18-1·92); p=0·0016) and the ER-
positive subgroup (HR (CI 95%): 1·55 (1·18-2·04); p=0·00020), but not in ER-
negative  tumours (HR (CI 95%): 1·58 (0·97-2·56), p=0·065) (Fig.2A-C); METABRIC 
cohort.   
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As continuous variables, high SPAG5-transcript expression levels was associated 
with shorter BCSS than low SPAG5-transcript [ND cohort: (HR (CI 95%):1·50 (0·98-
2·32); p=0·065), Uppsala cohort: (HR (CI 95%): 1·99 (1·44-2·76); p<0·0001) and 
METBRIC cohort: (HR (CI 95%): 1·89 (1·55-2·31); p<0·0001)].  As a categorical 
variable high SPAG5-transcript (>median), was associated with shorter BCSS than 
low SPAG5-transcript [Uppsala: (HR (CI 95%): 1·98 (1·29-3·04); p=0·0020), and 
METABRIC: (HR (CI 95%): 1·68 (1·40-2·01); p<0·0001, Fig2D).  High SPAG5-
transcript was associated with shorter BCSS than low SPAG5-transcript in ER-
positive sub-groups but not in ER-negative tumours (Fig.2E-F). Also, in the low-risk 
BC (NPI≤3·4), LN-negative, as well as LN-positive (METABRIC), high SPAG5 
transcript was associated with shorter BCSS than low SPAG5 transcript (Figure 
appendix 42). In Uppsala cohort with 249 cases (124 in the high SPAG5 transcript 
group) achieved a power of 83% to detect a hazard ratio (HR) of 1·98 , when the 10 
years survival rate for high and low SPAG5 transcript are 53% and 71%; respectively 
with p value <0.050.  Similarly for the METABRIC cohort transcript expression 
analysis, a power model using a two-sided log-rank test with an overall sample size 
of 1950 subjects (970 in the high SPAG5-transcript groups) achieved a power in 
excess of ≥99·9% to detect a hazard ratio (HR) of 1·68, when the proportion 
surviving (BCSS) to 10 years in the high SPAG5 and low SPAG5 are 78% and 66%; 
respectively, with p <0·0001.   
In untreated LN-negative cohorts high SPAG5 transcript (>median) was associated 
with shorter DSF, DRFS and BCSS than low SPAG5 transcript (Fig.2G-I]. In the 
untreated LN-negative-BC cohorts: Wang et al (n=286; 143 cases with high SPAG5), 
Schmitt et al (n=200; 100 cases with high SPAG5), and Desmedt et al (n=198; 99 
cases with high SPAG5), the retrospective power of each to detect HRs of 1·3, 1·4, 
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and 1·99 at ten year for DFS, DRFS and BCSS was 82%, 84%, and 98%; 
respectively, with p<0·050.   
In the Uppsala cohort multivariable Cox regression analysis including patient age, 
LN-stage, tumour-size, GGI, ER status, and MKi67-transcript, revealed that high 
SPAG5-transcript and LN-stages were independently associated with increased-risk 
of death (Table-1A).  Similarly in the METABRIC cohort, a multivariable Cox 
regression model which included patient age, tumour size, grade, LN-stage, HER2, 
ER, PR, hormone-therapy, and chemotherapy, demonstrated that high SPAG5-
transcript was independently associated with shorter BCSS (Table-1B).  
Furthermore, multivariable Cox regression models showed that high SPAG5-
transcript was associated with clinical outcome independently of both PAM50 and 
intClust prognostic subclasses (Table 1C-D).  Furthermore, in the untreated LN-
negative Desmedt et al cohort, high SPAG5-transcript was associated with shorter 
BCSS after adjustment for ER status and other prognostic signatures/indices such 
as 76-gene prognostic signature (Veridex)13, Adjuvant-Online (AOL) and the 
Nottingham Prognostic Index (Table 1-E). 
In the MCC cohort high SPAG5-transcript (>median) was associated with increased 
risk of relapse compared to low SPAG5-transcript expression in all patients and LN-
negative, LN-positive, and ER-positive BC subgroups, but not in the ER-negative-
subgroup (Figure appendix p43).  In MCC, with an overall sample size of 5439 (2711 
in high SPAG5), a ≥99·9% power to detect a HR of 1·68 for DFS, with p-value 
<0·0010, was achieved.  In the MCC cohort, multivariable Cox regression models 
confirmed that the high SPAG5-ranscript is an independent poor prognostic factor 
after controlling for NPI (HR (CI 95%): 1·19 (1·09-1·30); p=0·00020), AOL (HR (CI 
95%): 1·18 (1·03-1·35); p=0·017), and 72-proliferation-gene-signature 29 (HR (CI 
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95%): 1·18 (1·10-1·27); p<0·0001). Univariate analysis showed that high MKi67 
transcript expression was associated with a higher risk of relapse compared to low 
MKi67 expression. However, multivariable Cox regression models revealed that 
MKi67 transcript expression was not an independent prognostic factor for BC after 
controlling for NPI (HR (CI 95%): 1·09 (1·00-1·20); p=0·060) and AOL (HR (CI 95%): 
0·93 (0·83-1·05); p=0·26). 
Similarly high SPAG5-protein expression was associated with shorter BCSS than 
low SPAG5-protien expression (ND: HR (CI 95%): 1·06 (1·02-1·09), p=0·0010, and 
Nottingham-HES-BC cohorts: HR (CI 95%): 1·68 (1·32-2·12), p<0·0001; Fig.3A]. 
High SPAG5-protein was also associated with increased-risk of death in ER-positive 
subgroups (Fig.3B), but not in ER-negative subgroups (Fig.3C). In the low-risk 
(NPI<3·4), LN-negative, as well as LN-positive subgroups SPAG5 protein was 
associated with shorter BCSS (Figure appendix p44). For the ND and Nottingham 
HES BC cohort, with an overall sample size of 128 and 1342 subjects (24 and 273 
cases in the SPAG5-protein+ subgroups), 80% and 99·0% powers to detect a HR of 
1.10 and 1·68 is achieved with p-value <0·05, when the proportion surviving in the 
high SPAG5 subgroup at ten year of BCSS is 60% and 63%; respectively.   
Multivariable Cox regression analysis reveals that high SPAG5-protein was 
independently associated with a poorer BCSS at 10 years, after adjustment for 
adjuvant hormone-therapy and chemotherapy, grade, size, LN-stage, HE2, ER, PR, 
age, Ki67 and interaction-terms (SPAG5* chemotherapy and SPAG5* hormone-
therapy); Table 1F.  
In the Nottingham-ER-negative cohort, high SPAG5-protein was associated with 
decreased risk of death from BC (HR (95% CI): 0·85 (0·78-0·94); p=0·0010) (Fig.3D) 
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compared to low SPAG5-protein expression. However, a subgroup analysis of 
adjuvant-chemotherapy-naïve cases showed that patients with high and low SPAG5-
protein expression exhibited similar BCSS (HR (95% CI): 0·90 (0·63-1·27); p=0·54), 
whereas in the subgroup that received adjuvant-chemotherapy; high SPAG5-protein 
exhibited lower risk of death (HR(95% CI): 0·41 (0·26-0·64); p<0·0001) compared to 
low SPAG5-protein level (Figure appendix p45). In ER-negative BC with high 
SPAG5-protein, administration of anthracycline-ACT had reduced the risk of death 
by 60% compared to chemotherapy-naive (HR (95% CI): 0·37 (0·20-0·60); 
p=0·0010) (Fig.3E). Meanwhile administration of anthracycline-ACT had no impact 
on tumours with ER-negative /low SPAG5-protein phenotype (Fig.3F). A 
multivariable Cox regression model confirms that SPAG5 was a predictive marker 
and that the interaction-term between SPAG5-protein and the administration of 
anthracycline-based adjuvant chemotherapy was a significant predictor for BCSS 
(Table-1G). 
In the MDACC-T/AC-Neo-ACT cohort, after receiving combination cytotoxic 
chemotherapy, there was a marginally shorter DRFS in those patients with high 
SPAG5-transcript tumours compared to low SPAG5 transcript (HR (CI 95%): 1·3 
(0·92-1·95); p=0·12; appendix p43). In those patients that did not achieve pCR, high 
SPAG5-transcript was significantly associated with shorter DRFS than those with low 
SPAG5-transcript (HR (CI 95%): 1·74 (1·17-2·52); p=0·0070; appendix p46). A 
multivariable Cox regression analysis which included other prognostic factors for 
chemotherapy, namely genomic-chemo-sensitivity predictor, GGI, DLDA30, PAM-50-
genes, American joint committee of cancer (AJCC) stages, and MKi67 transcript, 
revealed that high SPAG5 was independently associated with decreased risk of 
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distant relapse after receiving Neo-ACT (HR (CI 95%): 0·68 (0·48-0·97); p=0·0070; 
Table1H). 
To validate our previous observation, we investigated the relationship of SPAG5 
transcript expression and response to combination cytotoxic chemotherapy in the 
MDACC-T/AC-Neo-ACT cohort (n=508) in which 488 cases had pCR data were 
available.  Of them, 20% (99/488) achieved pCR.  As a continuous variable, high 
SPAG5-transcript levels were associated with higher pCR compared to low SPAG5-
transcript (OR (CI 95%): 2·6 (1·8-3·9); p<0·0001).  As a categorical variable, high 
SPAG5-transcript (>median) was association with higher pCR; 29% (70/246) vs 12% 
(29/242) for low SPAG5-transcript (OR (95% CI): 2·90 (1·80-4·70), p<0·0001). 
Multivariable logistic regression analysis including parameter/indices/subclasses that 
associated with higher pCR as well as: AJCC clinical stage, histological grade, ER, 
PR, and patient age, demonstrated that high SPAG5-transcript was an independent 
predictor for higher pCR (Table-2A).   
We further validated our results in a multicentre phase II anthracycline-based-Neo-
ACT clinical trial cohort (NCT00455533) 20 in which 27% (69/253) and 34% (86/253) 
of patients achieved pCR and RCB-0/RCB-1 rates, respectively.  As a continuous 
variable, SPAG5-transcript expression was associated with a marginally higher 
incidence of pCR and RCB-0/RCB-1 ((OR (CI 95%): 1·33 (0·98-1·79); p=0·065) and 
(OR (CI 95%): 1·29 (0·98-1·71); p=0·075); respectively).  Using the median to 
categorize SPAG5-transcript expression into (high) and (low); high SPAG5-transcript 
was associated with higher pCR and RCB-0/RCB-1 rates ((OR (CI 95%): 1·99 (1·13-
3·45); p=0·016) and (OR (CI 95%): 1.97 (1·16-3·34); p=0·010), respectively) 
compared to low SPAG5-transcript. In a multivariable logistic regression model 
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which included ER, PR, Her2, tumour size, menopausal status, and MKi67, and 
SPAG5 transcript expression, SPAG5-transcript was significantly associated with 
RCB-0/RCB-1 (Table 2B). 
Similar to transcriptomic findings, patients with high SPAG5-protein (H-score>10) 
disease prior to chemotherapy, who received AC-Neo-ACT, exhibited similar 5-year 
DFS following surgery (HR (95% CI): 1·1 (0·90-1·30); p=0·40) to those with low 
SPAG5-protein- disease (appendix p43). Importantly, patients with high SPAG5-
protein expression in the residual tumour specimen after receiving AC-Neo-ACT 
were at a higher risk of relapse (HR (95% CI): 2·2 (1·2-4·2); p=0·010) compared to 
those with low SPAG5-protein residual tumours, at the 5-year follow-up (Figure 
appendix p46). In the Nottingham-AC-Neo-ACT cohort, 14·5% (29/200) of patients 
had achieved pCR and 40% (20/50) of patients with high SPAG5-protein BC 
achieved pCR compared to 6% (9/150) of those with low SPAG5-protein- disease 
(OR (CI 95%): 10·8 (4·5-26·29); p<0·0001; appendix p43). Furthermore, 37% 
(18/49) of BC that exhibited high SPAG5-protein disease became negative for 
SPAG5-protein after receiving AC-Neo-ACT (McNemar-test; p=0·0040).  
Multivariable logistic regression analysis revealed that high SPAG5-protein+ was an 
independent predictor for pCR, whereas Ki67 was not, after controlling for age, 
taxane, grade, AJCC stage, ER, HER2, Ki67, Bcl2, and TOP2A (Table-2C).   
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Discussion 
To our knowledge this is the first multi-dimensional study to report on the clinico-
pathological utilities of SPAG5 in BC in more than 10,000 patients. Our findings 
suggest that: 1) Amplification/gain of the SPAG5 locus at Ch17q11·2 occurred in 10-
20% of BC, 2) The SPAG5-gene-CNA and its transcript and protein were associated 
with poor clinical outcome and adverse clinicopathological features, including TP53-
mutation, PAM50-LumB, and PAM50-Her2, 3) Both SPAG5 transcript+ and protein+ 
are independent predictors for response to chemotherapy.  
Recent advances in molecular biology have generated a huge amount of data, which 
has then been used to generate multigene-profiles for guiding chemotherapy 
treatment. Unfortunately, almost all of these approaches face common issues such 
as insufficiently high levels of evidence, the over-fitting of computational models, 
false discovery rates, 30 and the lack of a potential biological mechanism to support 
their use as predictors of therapeutic response. Furthermore, they do not offer a 
significant improvement in predictive accuracy over the well-established pathological 
parameters or the cheaper, conventional immunohistochemistry approach, and may 
not be available for logistical or financial reasons. 31 In fact, the majority of the 
prognostic power of these assays comes from genes that are related to cell 
proliferation. The data presented herein are significant as the prognostic and 
predictive capacities of SPAG5 have been shown to be independent of many of 
these multigene tests and Ki67. Furthermore, our integrated network inference 
bioinformatics analysis has revealed that MKi67 was less influential on other 
proliferation factors, and lacked the centrality of other probes.   
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In agreement with the results of data mining the Oncomine-microarray database, we 
found BC, like most human cancers, exhibited a higher level of SPAG5-transcript 
expression compared to normal tissue (appendix 47-53), which in turn is associated 
with poor clinical outcome (appendix 54-56), especially in ER-positive BC. 25 In 
agreement with a previous study, we have reported a high level of Ch17q11·2 
amplifications in HER2-overexpression and ER-positive BC, 32 which is the locus of 
SPAG5. Recently, duplication of CEP17 has been proposed as a marker of 
chromosomal instability, spindle assembly checkpoint deregulation, and it has been 
linked to anthracycline-sensitivity in vitro and to clinical outcome of AC-ACT. 33 
Likewise, given that SPAG5 has an essential role in the progression of the cell cycle 
during the mitotic phase, SPAG5 dysregulation could contribute to chromosome 
instability and aneuploidy, both of which are hallmarks of malignant cells and could 
confer vulnerability on the cancer cell. Given that drugs such as the anthracyclines 
and taxane, which interfere with the normal progression of mitosis, belong to the 
most successful chemotherapeutic compounds that are currently used for anti-
cancer treatment, SPAG5 could be a molecular target on which the development of 
“next generation anti-mitotic drugs” could be based.  Recent studies in cervical 
cancer 34, 35 reported SPAG5 to be up-regulated, and demonstrated that the down-
regulation of SPAG5 inhibited cell proliferation/growth, increased apoptosis and 
hindered cell migration and invasion. 35 Furthermore, it is possible that “anti-SPAG5 
agents” could sensitize resistant BC cells to current treatment regimens.   
The potential clinical significance of our results primarily relates to the identification 
of BC patients who are likely to benefit from anthracycline-based chemotherapy. 
Validating our results in a randomized-prospective Neo-ACT trial would allow 
patients whose tumour response would be poor to be spared from enduring the 
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unnecessary risk of cardiac toxicity, when other more effective agents can be used. 
Although the mechanism linking SPAG5+ and response to anthracycline is unknown 
and further investigation is warranted, it could be due to the accumulation of DNA 
damage, abnormal mitoses, and subsequent mitotic catastrophe.36  
In summary, our findings have the potential to introduce an accurate predictive 
biomarker for chemotherapy response, which would facilitate the effective tailoring of 
BC treatment. This work may lead to the development of novel therapeutic strategies 
for treating a subtype of BC, thereby increasing the chance of cure from BC.  
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Abbreviations 
AC = anthracycline combination 
AC-ACT = anthracycline combination adjuvant chemotherapy 
ACT = adjuvant Taxane chemotherapy (Docetaxel 75 to 100mgm-2 every 3 weeks) 
ANN = artificial neural network 
AOL = Adjuvant-Online 
AR = androgen receptor 
ASCO = American society of clinical oncology 
BC = breast cancer 
BCSS = breast cancer specific survival 
CAP = college of American pathologists 
CI = confidence interval 
CNA = copy number aberrations 
CMF = cyclophosphamide 750 mg m−2, methotrexate 50 mg m−2 and 5-fluorouracil 1 
g m−2, on day 1 of a 21-day cycle. 
DFS = disease-free survival 
DM = distant metastasis  
DRFS = distant metastasis-free survival 
ER = oestrogen receptor  
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FEC/FAC = 5-Fluorouracil (5-FU) 500 mg m−2, Epirubicin 75–100 mg m−2, 
Cyclophosphamide 500 mg m−2, on day 1 of a 21-day cycle. 
FFPE = formalin-fixed paraffin embedded 
HER2 = human epidermal growth factor receptor 2 
HR = hazard ratio 
HPA = human protein atlas 
IHC = immunohistochemistry 
LAP-BC = locally-advanced primary breast cancer 
LN = lymph node 
MDACC-T/AC-Neo-ACT = University of Texas MD Anderson Cancer Centre-
Taxane/Anthracycline-based neo-adjuvant chemotherapy cohort 
MCC = Multicentre combined cohort 
MCCV = Monti Carlo cross validation 
MI = mitotic index 
ND = Nottingham discovery cohort 
Neo-ACT = neo-adjuvant chemotherapy 
Nottingham-AC-Neo-ACT = Nottingham anthracycline-Neoadjuvant-chemotherapy 
cohort 
Nottingham-ER- = Nottingham early stage ER- BC cohort 
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Nottingham-HES-BC = Nottingham historical early-stage-primary BC cohort 
NPI = Nottingham prognostic index 
NT = Nottingham series 
pCR = pathological complete response 
PR = progesterone receptor 
TMA = tissue microarray 
TNBC = triple negative breast cancer 
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Tables 
Table-1: Multivariable Cox regression models analysis in different breast cancer 
cohorts. 
 
A. Multivariable Cox regression model analysis for breast cancer specific survival 
in the Uppsala test cohort (SPAG5 transcript) (n=249) 
Variables HR 95·0% CI P value 
Lower Upper 
SPAG5 mRNA (high) 1·62 1·03 2·53 0·036* 
MKI67 mRNA (high) 0.991 0.486 1.71 0·77 
Lymph node status (positive) 1·61 1·01 2·57 0·050*
 
96-gene genomic grade index (GGI) 
26 
 
G1 
G2a 
G2b 
G3 
 
 
1 
0·94 
1·77 
1·73 
 
 
 
0·50 
0·82 
0·76 
 
 
 
1·79 
3·96 
3·97 
0·34 
Age at diagnosis** 1·01 0·99 1·03 0·16 
Tumour size (continuous) (mm) 1·09 0·95 1·24 0·21
 
Oestrogen receptor (positive) 1·43 0·76 2·71 0·27 
TP53 mutation 1·07 0·62 1·86 0·80 
B. Multivariable Cox regression model (1) analysis for breast cancer specific 
survival in the METABRIC cohort (SPAG5 transcript) (n=1980) 
SPAG5 mRNA (high) 1·27 1·02 1·58 0·034* 
Lymph node (LN) stage 
Negative 
1-3 positive LNs 
>3 positive LNs 
 
1·00 
1·68 
3·42 
 
 
1·31 
2·59 
 
 
2·16 
4.52 
<0·0001* 
Histologic grade 
Low 
Intermediate 
High 
 
1·00 
1·79 
2·05 
 
 
1·08 
1·23 
 
 
2·95 
3·39 
0·017* 
Size 1·01 1.007 1·015 <0·0001* 
Age at diagnosis** 1·01 1·002 1·02 0·015* 
HER2 1·50 1·18 1·91 0·0010*  
Progesterone receptor (positive) 0·77 0·62 0·96 0·020* 
Oestrogen receptor (positive) 1·06 0·78 1·45 0·70 
Hormone therapy 1·23 0·82 1·02 0·12 
Chemotherapy 1·31 0·96 1·78 0·090 
Hormone therapy*SPAG5 0·62 0·41 0·93 0·021* 
Chemotherapy*SPAG5 0·84 0·55 1·28 0·42 
C. Multivariable Cox regression model (2) analysis for breast cancer specific 
survival in the METABRIC cohort (SPAG5 transcript) (n=1980) 
SPAG5 mRNA (high) 1·31 1·04 1·65 0·020* 
PAM-50 Molecular subclasses 
28 
PAM50-LumA 
PAM50-LumB 
 
1 
2·13 
 
 
1·62 
 
 
2·80 
<0·0001* 
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PAM50-HER2 
PAM50-Basallike 
PAM50-Normal 
2·34 
1·89 
1·45 
1·72 
1·38 
1·01 
3·18 
2·59 
2·08 
Hormone therapy 1·31 1·06 1·60 0·010* 
Chemotherapy 1·31 1·66 2·59 <0·0001* 
Hormone therapy*SPAG5 0·57 0·38 0·84 0·0050* 
Chemotherapy*SPAG5 1·18 0·78 1·78 0·43 
D. Multivariable Cox regression model (3) analysis for breast cancer specific 
survival in METABRIC cohort (SPAG5 transcript) (n=1980) 
SPAG5 mRNA (high) 1·33 1·06 1·67 0·014* 
Integrated Clusters (IntClust)
11 
intClust.1 
intClust.2  
intClust.3  
intClust.4  
intClust.5  
intClust.6  
intClust.7  
intClust.8  
intClust.9  
intClust.10 
 
1 
1·47 
0·38 
0·69 
1·58 
1·13 
0·58 
0·65 
1·08 
0·75 
 
 
0·92 
0·24 
0·46 
1·09 
0·70 
0·37 
0·44 
0·72 
0·50 
 
 
2·34 
0·61 
1·03 
2·30 
1·81 
0·93 
0·97 
1·63 
1·13 
<0·0001* 
Hormone therapy 1·23 1·003 1·50 0·047* 
Chemotherapy 2·02 1·62 2·51 <0·0001* 
Hormone therapy*SPAG5 0·53 0·36 0·77 0·020* 
Chemotherapy*SPAG5 1·18 0·78 1·78 0·66 
E. Multivariable Cox regression analysis of SPAG5 transcript in untreated Lymph 
node negative “Desmedt cohort” 
SPAG5 mRNA (high) 2·34 1·24 4·42 0·0090* 
Oestrogen receptor (positive) 0·67 0·38 1·22 0·19 
NPI 1·74 0·712 4·23 0·22 
Adjuvant-online (AOL) 0·76 0·30 1·94 0·56 
76-gene prognostic signature (Veridex) 
13 1·52 0·75 3·06 0·24 
F. Multivariable Cox regression analysis of SPAG5 protein for breast cancer-
specific survival at 20 years follow-up in Nottingham historical early stage 
breast cancer cohort (n=1650) 
SPAG5 protein expression (positive) 1·73 1·23 2·46 0·0020* 
Tumour size (continuous) (mm) 1·18 1·07 1·31 0·0010* 
Lymph node (LN) status  
Negative  
Positive 
 
1 
1·95 
 
 
1·51 
 
 
2·52 
<0.0001* 
Histological grade  
Low/intermediate  
High 
 
1 
1·83 
 
 
1·33 
 
 
2·50 
0·00020* 
Oestrogen receptor (positive) 1·20 0·82 1·74 0·350 
HER2 overexpression (positive) 1·60 1·16 2·52 0·0040* 
Progesterone receptor status (positive) 0·66 0·47 0·92 0·015* 
Ki67 (positive) 1·44 1·03 2·01 0·034* 
Chemotherapy status (CMF) 1·55 1·13 2·17 0·010* 
Hormone therapy (yes) 1·31 0·99 1·73 0·059 
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Chemotherapy*SPAG5 1·65 0·85 3·23 0·14 
Hormone therapy *SPAG5 1·95 1·14 3·35 0·015* 
G.  Multivariable Cox regression analysis of SPAG5 protein for breast cancer-
specific survival at 10 years follow-up in Nottingham early stage oestrogen 
receptor negative breast cancer cases (n=697) 
Model without interaction terms 
SPAG5 protein expression (positive) 0·68 0·50 0·92 0·013* 
Tumour size (continuous) 1·06 1·02 1·09 0·0010*
 
Lymph node (LN) status  
Negative  
Positive 
 
1 
2·60 
 
 
1·92 
 
 
3·50 
<0·0001
*
 
Histological grade  
Low/intermediate  
High 
 
1 
1·67 
 
 
0·98 
 
 
2·86 
0·059 
Menopausal status (post vs pre) 1·34 0·99 1·82 0·060 
HER2 overexpression (positive) 0·92 0·64 1·31 0·64
 
Bcl2 (positive) 0·60 0·40 0·90 0·013* 
Chemotherapy status  
 
No Chemotherapy  
CMF  
Anthracycline 
 
 
1 
0·80 
0·61 
 
 
 
0·54 
0·42 
 
 
 
1·18 
0·89 
 
 
 
0·260 
0·010* 
Model with interaction terms 
SPAG5 protein expression (positive) 0·48 0·30 0·76 0·0020* 
Tumour size (continuous) 1·05 1·02 1·09 0·0030*
 
Lymph node (LN) status  
Negative  
Positive 
 
1 
2·57 
 
 
1·90 
 
 
3·46 
<0.0001* 
Histological grade  
Low/intermediate  
High 
 
1 
1·65 
 
 
0·97 
 
 
2·82 
0·066 
Menopausal status (post vs pre) 1·35 0·99 1·84 0·056 
HER2 overexpression (positive) 0·93 0·65 1·34 0·70 
Bcl2 (positive) 0·63 0·42 0·94 0·023 
Chemotherapy status  
No Chemotherapy  
CMF  
Anthracycline 
 
1 
0·79 
0·59 
 
 
0·54 
0·40 
 
 
1·16 
0·87 
 
 
0·23 
0·008* 
SPAG5*CMF interaction term 0·70 0·32 1·50 0·36 
SPAG5*Anthracycline interaction term 0·43 0·20 0·93 0·032* 
H. Multivariable Cox regression analysis for clinical outcome (distant relapse-free 
survival (DRFS)) in the University of Texas MD Anderson Cancer Centre 
Taxane/Anthracycline based neo-adjuvant cohort (n=508) 
SPAG5 transcript expression (positive) 0·68 0·48 0·97 0·031* 
Chemo-sensitivity prediction signature 
19 
Low vs high 
 
0·49 
 
0·36 
 
0·67 <0.0001* 
96- gene genomic grade index (GG1) 
26 
Grade 1/Grade2a vs Grade 2b/Grade 3-like 0·646 0·323 1·29 0·21 
30-gene (DLDA30)
27 2·09 0·95 4.56 0·065 
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Low vs High 
PAM-50 Molecular subclasses 
28 
PAM50-LumA vs others 
PAM50-LumB vs others 
PAM50-HER2 vs others 
PAM50-Basal-like vs others 
 
0·16 
0·24 
0·14 
0·28 
 
0·04 
0·07 
0·03 
0·07 
 
0·58 
0·88 
0·66 
1·10 
0·042* 
0·0060* 
0·031* 
0·013* 
0·068 
Clinical AJCC stage 
I/II vs III 
 
2·03 
 
1·38 
 
2·99 
 
0·00040*
 
MKI67 transcript 1·22 0·71 2·07 0·47 
 
*Statistically significant at p<0·05. 
**Age was a continuous value with increments of 5 years. 
SPAG5; Sperm-associated antigen, ER; Oestrogen receptor; HER2; Human 
epidermal growth factor receptor 2, Bcl2;  B-cell CLL/lymphoma 2; GG;I genomic 
grade index, IntClust; Integrated Clusters; DLDA: diagonal linear discrimination 
analysis, AJCC; American Joint Committee of Cancer.   
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Table-2: Multivariable logistic regression models analysis for pathological complete 
response (pCR) or residual cancer burden (RCB) in neo-adjuvant.  
 
A. Multivariable logistic regression models analysis for pathological 
complete response (pCR) in the Nottingham anthracycline-based neo-
adjuvant BC cohort (SPAG5 protein expression) 
Variables OR 
95.0% CI 
P value 
Lower Upper 
SPAG5 protein expression (high) 8·75 2·42 31·62 0·0010* 
Ki67 protein expression (high) 2·81 0·77 10·24 0·11 
Bcl2 protein expression (positive) 0·19 0.05 0·69 0·010* 
TOP2A protein expression 
(overexpression) 
3·81 0·98 14·73 0·053 
ER protein expression (positive) 0·77 0·42 2·84 0·25 
HER2 expression (overexpression) 0·84 0·23 3·12 0·79 
Taxane (yes) 0·67 0·21 2·21 0·52 
Age (continuous)** 1·04 0·98 1·10 0·25 
AJCC stage (i/II us III/IV) 0.35 0·109 1·52 0·084 
Histological Grade (G1/2 vs G3) 0·417 0·11 1·54 0·18 
B. Multivariable logistic regression models analysis for pathological 
complete response (pCR) in the University of Texas MD Anderson 
Cancer Centre Taxane/Anthracycline-based neo-adjuvant cohort 
SPAG5 transcript) (high) 1·71  1·07 2·74 0·024* 
Pathological Complete response 
(pCR) prediction signature  
Low vs high 
 
 
1·17 
 
 
0·44 
 
 
3·10 
0·75 
96- gene genomic grade index (GG1) 
26 
Grade 1/Grade2 a vs Grade 2 b/Grade 
3-like 
0·26 0·09 0·78 0·016* 
30-gene (DLDA30) 27 
Low vs High 
1·17 0·44 3·10 0·75 
PAM-50 Molecular subclasses 28 
PAM50-LumA vs others 
PAM50-LumB vs others 
PAM50-HER2 vs others 
PAM50-Basal-like vs o 
 
0·16 
0·24 
0·14 
0·28 
 
0·04 
0·07 
0·03 
0·07 
 
0·58 
0·88 
0·66 
1·10 
0·042* 
0·0060* 
0·031 * 
0·013 * 
0·068 
Clinical AJCC stage I/II vs III 0.31 0.76 0·45 0·012* 
Histological grade G1/G2 vs G3 2·37 1·15 4·89 0·020* 
Age of patients (continuous) 0·99 0·96 1·01 0·26 
Oestrogen receptor status (positive) 0·46 0·21 1·04 0·063 
Progesterone receptor  (positive) 1·09 0·86 1·39 0·47 
C. Multivariable logistic regression models analysis for residual cancer 
burden (RCB) in neo-adjuvant cohorts in Multicentre phase II neo-
adjuvant clinical trial cohort (NCT00455533; n=253) 
SPAG5 transcript) (high) 1·80  1·02 3·02 0·044* 
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Oestrogen receptor status (positive) 0·59 0·25 1·36 0·21 
Progesterone receptor  (positive) 0·41 0·02 1·02 0·042* 
HER2 (overexpression) 0·96 0·36 2·62 0·94 
Age (≥50 years) 0·40  0·22 0·73 0·0030* 
Size( ≥5cm) 0·59  0·32 1·09 0·090 
 
*Statistically significant at p<0·05 
**Age was a continuous value with increments of 1 year. 
 
SPAG5; Sperm-associated antigen, ER; Oestrogen receptor; HER2; Human 
epidermal growth factor receptor 2, TOP2A; Topoisomerase II alpha, Bcl2;  B-cell 
CLL/lymphoma 2; GG;I genomic grade index, IntClust; Integrated Clusters; DLDA: 
diagonal linear discrimination analysis, AJCC; American Joint Committee of Cancer 
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Figure legends 
Figure 1: Concept diagram presenting each of the patient cohorts along with a 
summary of the hypotheses and methodology applied to each.  
Figure 2 (A-F): Clinical outcome of SPAG5-gene-gain/amplification and 
transcript in the METABRIC cohort. Kaplan-Meier curves showing the relationship 
between SPAG5-gene-gain/amplification and breast cancer-specific survival (BCSS) 
in all patients (A), oestrogen receptor positive (ER-positive) (B), and ER- negative 
subgroups (C). Kaplan-Meier curves showing the relationship between SPAG5-
transcript expression and BCSS in all patients (D), oestrogen receptor positive (ER-
positive) (E), ER-negative (F). (G-I): Relationship between SPAG5 transcript 
expression and clinical outcome in untreated lymph node negative breast cancer 
(BC) cohorts.  Kaplan-Meier curves showing the relationship between SPAG5-
transcript expression and: relapse in Wang et al cohort (G), distant relapse in 
Schmidt et al (H), and death from BC in Desmedt et al cohort (I). See text for details.   
(Homo; loss of both gene alleles, hetero; loss of one copy of the gene), Neu; 2 
copies of the gene, Gain; >2 copies of the gene but <6 copies and Amp; 
amplification ≥6 copy of the gene)    
Figure 3 (A-C): Relationship between SPAG5-protein expression and clinical 
outcome in a large, well-characterized cohort of Nottingham Historical Early 
Stage BC cohort (n=1650). Kaplan-Meier curves showing the relationship between 
SPAG5-protein expression and breast cancer-specific survival (BCSS) in all patients 
(G), oestrogen receptor positive (ER-positive) (H) and ER- negative subgroups.   
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Figure 3 (D-F): Clinical outcome of ER-negative breast cancer stratified 
according to SPAG5-protein expression and adjuvant chemotherapy treatment 
status. Kaplan-Meier curves showing the relationship between SPAG5-protein 
expression and breast cancer specific survival (BCSS) in all ER-negative cohort 
cases (D).  E-F: Kaplan-Meier curves showing the relationship between the adjuvant 
chemotherapy protocols (no chemotherapy (No-CT), CMF (cyclophosphamide, 
Methotrexate and 5-Flourouracil) and anthracycline combination therapy) and BCSS 
in low SPAG5-protein expression (-) (E), and high SPAG5-protein expression (+) (F). 
See text for details.  
Supplementary figure legends: 
Supplementary-Fig.S1: Concept diagram summarizing the artificial neural network 
analysis methodology. 
Supplementary-Fig.S2 (A-B): Representative photomicrographs showing 
SPAG5-protein expression in breast cancer tissue. (A) Low SPAG5-protein 
expression (-) and (B) high Spag5-protein expression (+) in neoplastic cells 
(magnification x 200)  
Supplementary-Fig.S3: Gene interaction maps. Visualization of the top 100 
interactions of the common proliferation genes in the Nottingham discovery cohort, 
showing SPAG5 as a central hub(Cystoscope software). . 
Supplementary-Fig.S4: Gene interaction maps. Visualization of the interaction 
map of proliferation related factor KIF2C where SPAG5 again holds a prominent 
position (Cystoscope software). 
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Supplementary-Fig.5 (A-F):  SPAG5-gene copy number aberrations (CNA), as 
determined by SNP analysis in the METABRIC cohort. The SPAG5-gene-CNA in 
different histological grades (A), PAM50 molecular breast cancer subtypes: Basal-
like (Basal), HER2-enrich (HER2+), luminal A (LumA), Luminal B (LumB) and normal 
breast like (Normal). (B). Box-and-Whisker plots demonstrating the correlation 
between SPAG5 transcript expression and both its CNA (C), ER expression (D), 
molecular subclasses (E), and grade (F). (G-H): The relationship between 
integrative-clusters (Int-Clust1-10) and SPAG5 CNAs (G) and transcript (H). 
Supplementary-Fig.6 (A-F): Clinical outcome of SPAG5 transcript in the 
METABRIC cohort. Kaplan-Meier curves showing the relationship between SPAG5-
transcript and breast cancer-specific survival (BCSS) in low risk BC [Nottingham 
Prognostic index (NPI)<3·4] (A), lymph node negative (B), and lymph node positive 
(C) subgroups.   
Supplementary-Fig.7 (A-E): Relationship between SPAG5 transcript levels and 
clinical outcome in the combined multicentre cohort (MCC, n=5439). The forest 
plot showing the impact of SPAG5 transcript on survival in terms of hazard ratio (HR) 
and a confidence interval (CI) in different cohorts all at once provides a better 
(visual) insight into the variability of results between studies (A). Kaplan-Meier 
curves showing the relationship between SPAG5-transcript expression and the risk 
of relapse or death from breast cancer in oestrogen receptor positive (ER-positive) 
(B), ER- negative subgroups (C), lymph node negative (D), and lymph node positive 
(E).  
Supplementary-Fig.8 (A-C): Clinical outcome of SPAG5 protein in the 
Nottingham historical early stage breast cancer cohort. Kaplan-Meier curves 
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showing the relationship between SPAG5-transcript and breast cancer-specific 
survival (BCSS) in low risk BC [Nottingham Prognostic index (NPI)<3·4] (A), lymph 
node negative (B), and lymph node positive (C) subgroups.   
Supplementary-Fig.9 (A-E): Clinical outcome of Nottingham early stage ER-
negative breast cancer stratified according to SPAG5-protein expression and 
adjuvant chemotherapy treatment status. Kaplan-Meier curves showing the 
relationship between SPAG5-protein expression and breast cancer specific survival 
(BCSS) in: chemotherapy naïve patients (A), chemotherapy treated cohort (B), 
anthracycline naïve patients (C), and anthracycline treated cohort (D).   
Supplementary-Fig.10 (A-E): The relationships between SPAG5-protein and 
SPAG5-transcript expression and pathological complete response (pCR) rate 
and clinical outcome following anthracycline combined neo-adjuvant 
chemotherapy (AC-Neo-ACT) treatment with or without taxane.  Relationship 
between SPAG5-protein expression and pCR rate in the Nottingham Anthracycline-
based neo-adjuvant BC cohort (A). Kaplan-Meier curves illustrating the relationship 
between the expression of SPAG5-protein expression in core biopsies prior to 
chemotherapy (B) and in surgically removed residual tumour after chemotherapy, 
with breast cancer specific survival (BCSS) (C), see text for details.  (D-E): Kaplan-
Meier curves illustrating the relationship between the expression level of SPAG5-
transcript and distant relapse free survival (DRFS), in all cases (D) and in non-
pathological response cases with residual disease (E).  
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A detailed list of the reviewers’ comments and our responses 
In light the reviewers’ comments on the manuscript we have made a number of amendments 
to the document, each of which is listed below. 
Critique Reply 
Editorial Comments   
1. Please provide the appendix as a PDF, 
not a word document. 
 
The appendix has now been provided as a 
PDF file. 
 
 
2. Your figure files are not high enough 
resolution and are not editable by our 
production team. Please can I ask you 
to generate the figures using this 
information as a guideline: 
http://download.thelancet.com/pb/
assets/raw/Lancet/authors/artwork-
guidelines.pdf 
 
All figures have been checked and now 
meet the specifications for resolution and file 
type.  
 
 
3. Please indicate in your research in 
context panel, evidence before this 
study, that you weren't just interested 
in SPAG5 in particular (because you 
couldn't have known you wanted to 
look at it until you confirmed it in the 
ANN, right?) but in finding a biomarker 
that could be used in breast cancer, 
and that this was lacking (if I am 
correct in saying this?) 
 
The Research in context subsection 
“Evidence before this study”, has been 
rewritten to describe our initial work 
searching for novel BC biomarkers related 
to proliferation utilising an ANN analysis 
algorithm, which then developed in to the 
work on SPAG5 (p4) 
 
“There is an urgent need to find a novel 
biomarker that is associated with 
proliferation features in breast cancer and 
could potentially be used as a prognostic 
and/or predictive biomarker.  A non-linear 
artificial neural network (ANN) modelling 
based data mining approach and network-
inference algorithm was implemented for 
multiple proliferation related targets across 
in three breast cancer gene expression 
datasets to ascertain factors that could drive 
proliferation. The integrated findings 
identified SPAG5 featuring prominently in 
the interactome map and greatly impacting 
BC patient survival.  A PubMed search 
using the term “SPAG5” for publications up 
to 1st May 2012 retrieved 30 articles, only 
two of which reported on the overexpression 
of SPAG5 mRNA and clinical outcome in 
cancer. These reported on a small set of 
breast and lung cancers.  The majority of 
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the articles studied the biological function of 
SPAG5 in cell cycle progression, thereby 
providing evidence for its fundamental role 
in the function and dynamic regulation of 
mitotic spindles, mitotic progression, and the 
fidelity of chromosome segregation.” 
4. Reviewer 2 Q5: Explanation of 
converting to a common scale - please 
place this in the methods section of 
the appendix and refer to it in the text. 
 
The previous answer to this question has 
now been added to the text in the appendix 
and is referenced in the manuscript. 
Appendix page 8: 
 
Merging databases for MCC cohort:  
“In MCC cohort, gene expression data were 
converted to a common scale (median equal 
to 0 and standard deviation equal to 1) in 
order to merge all of the studies data and 
create combined cohorts. To convert to a 
common scale (the median equals to 0 and 
standard deviation equals to 1) and allow all 
studies to be merged, each sample in the 
data was standardised to a mean of 0 and 
standard deviation of 1. Then the data was 
median centred for each gene whereby 
median of each gene is 0.” 
 
5. Reviewer 2 Q9: Wherever 'coefficient' 
means 'correlation coefficient' please 
indicate this in the text. 
 
All incidents of “coefficient” in the text/tables 
and appendix have now been checked and 
amended to: 
“correlation-coefficient” 
 
6. Reviewer 2 Q12: If age was 
continuous with 5 year increments, 
please indicate this as a footnote in 
table 1. 
 
A footnote has been added to table 1: 
 
“Age was a continuous value with 
increments of 5 years.” 
 
7. Please put a footnote in table 1 to 
define GGI and IntClust and provide 
the references there that you've 
provided in your response (ed pt. 3).  
 
A footnote has been added to table 1 to 
define GGI and IntClust, in line with the 
previous response (ed pt. 3), and the 
references have been included. 
 
8. Please make clear in your flow 
diagram that the untreated lymph node 
negative cohorts are made up of 3 
cohorts, and the number of patients in 
each cohort. 
 
Figure 1 has been amended to clarify the 
untreated lymph node negative cohorts. 
 
 
9. In the flow chart, it says that 332 ER-
negative patients from the Nottingham 
historical early stage BC cohort were 
used in the chemotherapy assoc. part 
The numbers of cases for the ER-negative 
cohorts have been checked and corrected. 
 
All instances of referring to the ER status as 
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of your study but there are only 303 
patients that were ER-negative in this 
cohort - please clarify. Part of the 
confusion may be due to the fact that 
you are not clear in the text whether 
patients were ER-negative or positive. 
Please use the words negative and 
positive, rather than indicating 
negative as 'ER-'. 
 
ER- and ER+ in the manuscript, appendix 
and tables, have been checked and 
amended to ER-negative and ER-positive. 
   
 
10. Please indicate in the methods section 
(cohorts section) that the 697 patients 
in the Nottingham early stage ER-
negative BC cohort are from the 
historical cohort (303 or 332?) and the 
new early stage ER-negative cohort 
(365). Because the new cohort only 
supplies patients for the 
chemotherapy-association part of the 
study, please only place these patients 
in the bottom half of the flow chart - it 
is confusing to have them in the top 
because I cannot find any data from 
this cohort in the validation section of 
the results. 
 
The following text has been added (p13):  
“This series included: 1) The ER-negative 
BC patients of Nottingham historical early 
stage BC cohort (n=332) who were 
managed before 2000 and treated with 
either no chemotherapy or adjuvant CMF, 
and 2) the new ER-negative early stage BC 
patients (n=365) who were managed after 
2000 and received either no chemotherapy 
or anthracycline-based adjuvant 
chemotherapy (AC-ACT). 17” 
The cohort has been removed from the 
upper half of the flow chart and merged with 
ER-negative cohort in the bottom half 
11. Please revise the introduction to give a 
rationale for performing the ANN and 
other analyses (we do not report 
results in the introduction). Please add 
a sentence at the end of the 
introduction stating that the aim of the 
study was, for example, to identify a 
marker that could be used to stratify 
breast cancer patients. For example, 
in the procedures section of the 
methods in the first sentence you give 
the rationale for the ANN analysis - 
this could be placed in the 
introduction. 
 
The 2nd paragraph of the introduction has 
been revised as follows: (p9-10) 
 
“….The main aim of the current study was to 
identify a biomarker that could drive 
proliferation and could be used to stratify BC 
patients’ outcome. To achieve this, we 
decided to apply an artificial neural network 
(ANN) algorithm 6 to three gene expression 
datasets, and use factors that are directly 
and indirectly related to proliferation, defined 
as clinical class questions, to train it. The 
most prominent genes in the resulting 
interactome-map would then be developed 
and the best followed up, through an 
integrated analysis at the levels of copy 
number aberrations (CNAs), mRNA 
transcript and protein, in order to assess the 
clinico-pathological implications and utilities 
in a combined total of over 10,000 patients. 
Here we present the results of our ANN 
analysis, and the gene SPAG5 (Sperm-
associated antigen 5), which featured 
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prominently in the interactome -map of 
proliferation and had a great impact on 
patients’ survival.   Given that SPAG5 has a 
fundamental role in the function and 
dynamic regulation of mitotic spindles, and 
in mitotic progression and chromosome 
segregation fidelity, 7 we hypothesized that 
SPAG5 could be a better measurement of 
proliferation activity and provide a more 
accurate guide for the delivery of systemic 
therapies in BC.” 
12. In the discussion you reference a 
study that has already looked at 
SPAG5 association with breast cancer 
(#31). If this study was a part of your 
rationale for pursuing SPAG5 in your 
study, please indicate this in the 
results section when you talk about 
your ANN results. 
 
The following has been added to the text:  
 
“In addition, in a small set of BC, 
investigators found that SPAG5 transcript 
was a mong few genes that were associated 
with poor prognosis in ER-positive BC25”.  
 
P20 
13. Methods, validation cohorts: In the 
Nottingham historical early stage BC 
cohort, were all different treatment 
groups (pre-menopause, post-
menopause, etc.) group together in 
your analysis? 
 
In the Nottingham historical early stage BC 
cohort, we have done Cox regression 
multivariable analysis (Table 1F) controlling 
for ER, hormone therapy and 
chemotherapy. In addition we have 
controlled for other prognostic factors and 
included interaction terms between SPAG5 
and treatments (hormone therapy and 
chemotherapy).  In this analysis the main 
effect of SPAG5 was as an independent 
prognostic biomarker.  However, in 
univariate analysis we just presented (all 
patients, ER+, ER-, LN-, LN+ and low risk 
subgroups). P38-39 
14. The multicentre phase II cohort for the 
chemotherapy analysis had 295 
patients total, but only 253 with data. 
Please provide only the number with 
data (253) in figure 1 (this is consistent 
with the way you reported cohort size 
for the Uppsala cohort.) 
 
The number has been corrected in figure 1. 
15. Power analysis for false discovery: 
You say the desired sample size is 88 
(44 per class). What do you mean by 
class? 
 
The text in the introduction has been 
amended to provide this information: 
 
“To determine sample size, an alpha of 
0·05, a power of 0·80, an effect size (odd 
ratio = 1·72) and two-tailed test, were 
chosen for binary questions or classes (e.g., 
low vs., high expression).  Based on the 
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assumptions of the power model, the 
desired sample size is 88 (44 in each low 
and high class).” P19-20 
 
16. In the equation for the probability of 30 
gene occurring as common, where do 
the denominators come from (e.g, 
22283, 47289, 48803)? 
 
The denominators are the total number of 
gene probes available in each of the three 
cohorts. 
 
The following text has been added in 
appendix p8 and referred in main the text: 
  
Calculation of the probability (p) of the 30 
genes occurring as common in the top 100 
out of the whole expression array for the 
three cohorts for a minimum of 4 
proliferation-related factors can be 
calculated by:  
p= (Z/X1)s x (Z/X2)s x (Z/X3)s = 
(100/22283)4 x (100/47289)4 x 
(100/48803)4 = 1·43x10-31.   
X1 = Number of gene probes in Nottingham 
discovery cohort (ND) = 22283 
X2= Number of gene probes in Uppsala = 
47289 
X3= Number of gene probes in METABRIC 
= 48803 
Z= top target gene probe = 100 
S= minimum number of proliferation-related 
factors=4 
 
17. There are no power calculations for 
the Nottingham discovery cohort (171) 
or the Uppsala cohort (249). Were 
these not done? 
 
These have now been added to the text and 
moved to the result section 
“In Uppsala cohort with 249 cases (124 in 
the high SPAG5 transcript group) achieved 
a power of 83% to detect a hazard ratio 
(HR) of 1·98 , when the 10 years survival 
rate for high and low SPAG5 transcript are 
53% and 71%; respectively and p value 
<0.050.  p23 
 
“For the ND and Nottingham HES BC 
cohort, with an overall sample size of 128 
and 1342 subjects (24 and 273 cases in the 
SPAG5-protein+ subgroups), 80% and 
99·0% powers to detect a HR of 1.10 and 
1·68 is achieved with p-value <0·05, when 
the proportion surviving in the SPAG5+ 
subgroup at ten year of BCSS is 60% and 
63%; respectively.  “ p25 
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18. Please present all p values to 2 
significant figures (eg, 0.045 or 0.040) 
or if they are less than 0.0001 as 
p<0.0001. Please do not present them 
in scientific notation. 
 
All p-values have been checked and 
amended in the manuscript, tables, figures 
and appendix. 
 
 
19. Please place a description of the 
Monte Carlo cross-validation in the 
appendix (since the statistical reviewer 
asked for this). 
The description of Monte Carlo cross 
validation (MCCV) has been added in the 
appendix p8:  
 
“The MCCV strategy was applied to produce 
a better generalized model with an improved 
predictive ability for unseen or future cases. 
The MCCV randomly divided the samples 
into training (for model learning), test 
(assessing model performance during 
training by early stopping) and validation 
subsets (to independently test the model on 
unseen data) in a 60:20:20 ratio for 50 
iterations, as this was found to provide the 
most consistent models and no significant 
improvement was observed with more 
bootstraps. The algorithm was only run for 1 
step to produce single gene models over 10 
independent loops. A rank order of all the 
genes was produced based on the minimum 
average RMS error for the test subset 
across the 10 loops.” 
 
20. Your power calculation was done for 
"10 year survival" - does this include 
BCSS, DFS? Please be specific for 
each cohort. For the METABRIC 
power calculation you state that "the p 
value in this case was <0.0001." Is this 
the p value threshold? Or is it the 
predicted p value? Or is it the actual p 
value (if it's this, it needs to be in the 
results, not the methods)? Similar 
question for p values presented in this 
section for the LN-negative BC cohorts 
and the Nottingham HES BC cohort. 
 
The p value is the actual p value and 
subsequently the power of analysis section 
has been  revised  and most of it has been 
relocated to relevant cohorts in the result section 
(see p20, p23, p24 and p25 
 
“A retrospective power analysis was 
conducted to determine the confidence in 
the calculated hazard ratio and associated p 
value for 10 year survival and to ascertain 
how applicable the result would be to a 
global population.” P20. 
  
“In Uppsala cohort with 249 cases (124 in 
the high SPAG5 transcript group) achieved 
a power of 83% to detect a hazard ratio 
(HR) of 1·98 , when the 10 years survival 
rate for high and low SPAG5 transcript are 
53% and 71%; respectively and p value 
<0.050.  Similarly for the METABRIC cohort 
transcript expression analysis, a power 
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model using a two-sided log-rank test with 
an overall sample size of 1950 subjects (970 
in the high SPAG5-transcript groups) 
achieved a power in excess of ≥99·9% to 
detect a hazard ratio (HR) of 1·68, when the 
proportion surviving (BCSS) to 10 years in 
the high SPAG5 and low SPAG5 are 78% 
and 66%; respectively, with p <0·0001.” P23 
 
  “In the untreated LN-negative-BC cohorts: 
Wang et al (n=286; 143 cases with high 
SPAG5), Schmitt et al (n=200; 100 cases 
with high SPAG5), and Desmedt et al 
(n=198; 99 cases with high SPAG5), the 
retrospective power of each to detect HRs of 
1·3, 1·4, and 1·99 at ten year for DFS, 
DRFS and BCSS was 82%, 84%, and 98%; 
respectively, with p<0·050. “ p23-24 
 
 “In MCC, with an overall sample size of 
5439 (2711 in high SPAG5), a ≥99·9% 
power to detect a HR of 1·68 for DFS, with 
p-value <0·0010, was achieved. “ p24 
 
“For the ND and Nottingham HES BC 
cohort, with an overall sample size of 128 
and 1342 subjects (24 and 273 cases in the 
SPAG5-protein+ subgroups), 80% and 
99·0% powers to detect a HR of 1.10 and 
1·68 is achieved with p-value <0·05, when 
the proportion surviving in the SPAG5+ 
subgroup at ten year of BCSS is 60% and 
63%; respectively.  “ p25 
21. Results: you state that BC patients 
exhibited a higher level of SPAG5 
compared to normal individuals. These 
individuals have not been mentioned 
before - where do they come from? 
What are their baseline 
characteristics? This must be specified 
in the methods section. 
 
The following text has been added to 
methods section (p16): 
 “An additional analysis considered a set of 
85 individuals of European ancestry for 
whom genotyping was performed on non-
cancerous tissue and gene expression 
values from matched normal tissue were 
available11” 
22. Please describe all subgroups and 
subclasses studied in the methods 
section on clinicopathological and 
biomarker associations: p53, HER2, 
PAM50, intClust, etc.  
 
This has now been addressed in the text 
(p18) 
 
“The clinicopathological parameters 
including mainly: tumour size, lymph node 
stage, histological grade, genomic grade 
index (GGI), TP53 mutation, intrinsic 
molecular subclasses, PAM50, HER2 
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amplification/overexpression, hormone 
receptors, Ki67, mitotic index, Bcl2 and 
other biological biomarkers.”   
23. When you say that SPAG5 transcripts 
were higher - higher than what? 
Please define high and low for SPAG5 
transcript and protein. 
 
The level of SPAG5 expression, when 
described as a categorical variable, was 
produced by using the median as the cut 
point in each case. This is described in the 
text (p17):  
 
“Determination of the cut-offs 
The median in each cohort was used as cut-
off between low and high gene/protein 
expression.” 
 
In addition, the definition of high and low 
SPAG5 transcript and protein has been 
added to the text in relevant analysis in the 
result section sections (> median for the 
transcript) and (H-score>10 for the protein).  
   
24. Throughout the manuscript, please 
ensure that when you say something 
is higher or lower (higher expression, 
higher pCR, etc.) you include the 
comparator (eg, ER-negative patients 
had higher SPAG5 expression THAN 
ER-positive patients; pCR was higher 
in SPAG5-positive BC patients THAN 
in SPAG5-negative patients; etc.)  
 
This has now been addressed in the text. 
25. Please ensure that the data that you 
report for each cohort is consistent 
throughout the manscript. For 
example, if you report the number of 
patients who had a pCR in one cohort, 
please ensure that the number of 
patients who had this is reported in all 
cohorts that looked at pCR. Please 
report the 10 year or median BCSS, 
DFS, etc. for cohorts where this is 
known, and if subanalyses were done 
on subgroups in these cohorts, please 
provide these data for those groups as 
well. The appendix might be the 
appropriate place for these data. If 
these data are already present in the 
manuscript (eg, table 1, appendix), 
please just indicate that by referencing 
it in the text. 
This has now been addressed in the text 
and appendix table 1 p1-3. 
 
In addition the median BCSS, DFS, etc for 
each cohorts and subgroups analysis in 
these cohorts, has been provided in 
appendix Table 1 p1-3 and was referenced 
in the text. 
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Research in context 
Evidence before this study 
There is an urgent need to find a novel biomarker that is associated with proliferation 
features in breast cancer and could potentially be used as a prognostic and/or 
predictive biomarker.  A non-linear artificial neural network (ANN) modelling based 
data mining approach and network-inference algorithm was implemented for multiple 
proliferation related targets across three breast cancer gene expression datasets to 
ascertain factors that could drive proliferation. The integrated findings identified 
SPAG5 featuring prominently in the interactome map and greatly impacting BC 
patient survival.  A PubMed search using the term “SPAG5” for publications up to 1st 
May 2012 retrieved 30 articles, only two of which reported on the overexpression of 
SPAG5 mRNA and clinical outcome in cancer. These reported on a small set of 
breast and lung cancers.  The majority of the articles studied the biological function 
of SPAG5 in cell cycle progression, thereby providing evidence for its fundamental 
role in the function and dynamic regulation of mitotic spindles, mitotic progression, 
and the fidelity of chromosome segregation.  
Added value of this study 
To the best of our knowledge this is the first multi-dimensional study, withincluding 
more than 10,000 patients, multi-dimensional study to report on the 
clinicopathological utilities of SPAG5 in breast cancer. Our findings suggest that: 1) 
Amplification/gain of the SPAG5 locus at Ch17q11·2 occurs in 10-20% of all breast 
cancers; 2) The SPAG5-gene -copy number aberrations (CNAs) and its transcript 
and protein are associated with poor clinical outcome and adverse 
clinicopathological features, including TP53-mutation, PAM50-LumB, and PAM50-
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HER2; and 3) Both high expression of SPAG5 mRNA transcript and protein are 
independent predictors for response to chemotherapy.  
Implications of all the available evidence 
Our findings have the potential to introduce an accurate predictive biomarker for 
chemotherapy response, which would facilitate the tailoring of treatments to 
individual patients with breast cancer. This work may lead to the development of 
novel strategies for more effectively managing and treating a subtype of breast 
cancer.  
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Abstract =300 words 
Background: 
Although the use of proliferation markers/profiles has been recommended when 
choosing the appropriate systemic-treatment, the best molecular-marker/test that 
should be used needs to be identified.  Given that SPAG5 has a fundamental role in 
mitotic-progression, and is relatedassociated to with many features of proliferation, 
we hypothesized that SPAG5 could be a better measurementindicator of proliferation 
activity, and provide a more accurate guide for the delivery of systemic therapies in 
breast cancer (BC).  Subsequently we investigated the clinico-pathological utility of 
SPAG5: gene copy number aberrations (CNAs); mRNA and protein expression, in 
over 10,000 BCs.  
Methods: 
To identify factors that drive proliferation and its associated features in BC an 
artificial neural nNetwork (ANN) based integrative data-mining methodology was has 
been applied to three cohorts [(Nottingham-discovery (ND), Uppsala and METABRIC 
(Molecular Taxonomy of Breast Cancer International Consortium)],  Integrated 
analysis of SPAG5-gene CNAs, transcript and protein expression was further 
conducted in the Nottingham-discovery (ND cohort ) (n=171) and validated in the 
METABRIC cohort (n=1980). In addition, the associations of SPAG5 CNAs, 
transcript and/or protein with breast cancer specific survival (BCSS), disease free 
survival (DFS) and/or distant relapse free survival (DRFS) were analysed in multiple 
cohorts including Uppsala (n=249), METABRIC (n=1980), untreated lymph node 
negative cohorts (n=684), a combined multicentre clinical data set (n=5439), 
Nottingham historical early-stage-primary BC  (Nottingham-HES-BC; n=1650), 
Nottingham ER-negative BC (n=697), Nottingham anthracycline-Neoadjuvant-
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chemotherapy (Nottingham-AC-Neo-ACT; n=200), and MD Anderson Cancer Centre 
Taxane/anthracycline (MDACC-T/AC-Neo-ACT; n=508) cohorts. The association of 
SPAG5 transcript and protein expression with pathological response rate (pCR) were 
also tested in [MDACC-T/AC-Neo-ACT  (n=508) and the phase II trial 
NCT00455533; n=253)] and [Nottingham-AC-Neo-ACT (n=200)] cohorts; 
respectively.   
Findings: 
SPAG5 gene gain/amplification at the Ch17q11·2 locus was found in 10.4%; 
206/1980 (206/1980) 10.4%; METABRIC) of all BCs and in,  and was common in 
19·4% of PAM50-HER2 (46/237; 19·4%) and 17·8% of PAM50-LumB (87/488; 
17·8%) BC subclasses; METABRIC cohort. SPAG5-CNA -gain/amplification and 
high SPAG5-transcript and SPAG5-protein (+) were associated with increased risk of 
death from BC [(Uppsala; (HR (CI 95%): 1·50 (1·18-1·92); p=0·00010·0x10-4)p=1, 
METABRIC; (HR (CI 95%): 1·68 (1·40-2·01) p<0·0001), and Nottingham-HSE-BC; 
(HR (CI 95%): 1·68 (1·32-2·12), p<0·0001); respectively]). Multivariable Cox 
regression models, including other validated-prognostic factors, showed that 
SPAG5-transcript+ and SPAG5-protein+ were associated with shorter BCSS 
[(Uppsala: (HR (CI 95%): 1·62 (1·03-2·53) p=30·036*x10-2); (METABRIC: (HR (CI 
95%): 1·27 (1·02-1·58) p=30·034*x10-2); (untreated LN-negative cohort: (HR (CI 
95%): 2·34 (1·24-4·42) p=90·00900x*10-3), and (Nottingham-HES-BC (HR (CI 95%): 
1·73 (1·23-2·46) p=20·00200x*10-3); respectively].  
In ER-negative-BC with SPAG5-protein+, administration of anthracycline-adjuvant-
chemotherapy had reduced the risk of death by 6063% compared to chemotherapy-
naive (HR (95% CI): 0·37 (0·20-0·60); p=0·0010·0x10-3).  A multivariable Cox 
regression analysis, which included other validated prognostic factors for 
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chemotherapy, revealed that SPAG5-transcript+ was independently associated with 
decreased risk of DRFS after receiving Taxane/anthracycline-Neo-ACT [MDACC-
T/AC-Neo-ACT: (HR (CI 95%): 0·68 (0·48-0·97); p=70·00700x*10-3)]. 
In multivariable logistic regression analysis, both SPAG5-transcript+ and SPAG5-
protein+ and were independent predictors for higher pCR after combination-cytotoxic 
chemotherapy [MDACC-T/AC-Neo-ACT: (OR (95% CI) 1·71 (1·07-2·74); 
p=20·024*x10-2), and Nottingham-AC-Neo-AC: (OR (95% CI): 8·75 (2·42-31); 
p=0·0010); respectively].  
Interpretation:    
SPAG5 is a novel amplified gene on Ch17q11.2 in PAM50-LumB and PAM-HER2 
BC, and its transcript and protein products are independent prognostic and predictive 
biomarkers, with potential clinical utility as a biomarker for combination cytotoxic 
chemotherapy sensitivity, especially in ER-negative BC.   
Funding: 
Nottingham Hospitals Charity and the John and Lucille van Geest Foundation.   
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Words=3000 
Introduction 
Approximately 1·68 million women are diagnosed with BC worldwide annually, with 
over 500,000 dying of the disease (~1,400 per day).1  Despite continuing success, 
the delivery of effective precision medicine requires: 1) the discovery of novel 
therapeutic targets in subgroups of BC, and 2) improvements in the efficacy  of 
treatments by identifying stratification biomarkers that can predict an individual 
patient’s response to a particular therapy.2 Although chemotherapy is offered to 
approximately 60% of patients with BC,3 either alone or in combination with other 
targeted-therapies, a meta-analysis of 123 randomized trials involving over 100,000 
patients has concluded that chemotherapy reduces recurrence and mortality rates by 
only 20-33%.4  Although a St Gallen International Expert Consensus recently 
recommended the use of proliferation markers/profiles when choosing the 
appropriate systemic-treatment, the best molecular-marker/test that should be used 
continues to be debated.5 
The main aim of the current study was to identify a biomarker that could drive 
proliferation and could be used to stratify BC patients’ outcome. To achieve this, we 
decided to apply an artificial neural network (ANN) algorithm 6 to three gene 
expression datasets, and use factors that are directly and indirectly related to 
proliferation, defined as clinical class questions, to train it. The most prominent 
genes in the resulting interactome-map would then be developed and the best 
followed up, through an integrated analysis at the levels of copy number aberrations 
(CNAs), mRNA transcript and protein, in order to assess the clinico-pathological 
implications and utilities in a combined total of over 10,000 patients  ,The application Formatted: Font: 
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of a non-linear artificial -neural -network (ANN) modelling -based data mining 
approach and an ANN-based network-inference algorithm,6 to ascertain factors that 
could drive proliferation, to three BC gene expression datasets, identified a number 
of genes that featured prominently in the interactome -map and had the greatest 
impact on patients’ survival (one of which was SPAG5, see methodology and results 
section for details). Given. Here we present the results of our ANN analysis, and the 
gene SPAG5 (Sperm-associated antigen 5), which featured prominently in the 
interactome -map of proliferation and had a great impact on patients’ survival.   
Given that SPAG5  has a fundamental role in the function and dynamic regulation of 
mitotic -spindles, and in mitotic -progression and chromosome -segregation fidelity, 7 
we hypothesized that SPAG5 could be a better measurement of proliferation activity 
and provide a more accurate guide for the delivery of systemic therapies in BC. This 
study further undertook an integrated analysis of SPAG5 at the levels of copy 
number aberrations (CNAs), mRNA transcript and protein in order to assess the 
clinico-pathological implications and utilities of these in a combined total of over 
10,000 patients.  
Patients and Methods  
Study design and cohorts 
Study design, patient’s cohorts and demographics used in this study are summarized 
in Fig.1 and appendix p1-3. 
All patients completed written informed consented, as per hospital standard of care, 
for excess tumour tissue to be used in research. The study was approved by the 
Institutional Review Board or Independent Ethics Committee and the Hospital 
Research and Innovations Department at all participating sites. Tumour Marker 
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Prognostic Studies (REMARK) criteria, as recommended by McShane et al, 8 were 
followed throughout this study.  
I) Identification of proliferation deriversExploration and validation of the 
prognostic function of SPAG5-CNAs, transcript and protein expression in 
BC 
A) Discovery cohort: Nottingham discovery (ND) cohort (n=171) 
The ANN modelling-based data mining approach to identify factors that drive 
proliferation and its associated features in BC was explored in the ND cohort, 
consisting of a set of 171 stage I and II invasive BC with a median follow-up of 180 
months   (IQR 143-194), previously described by our group in several molecular 
profiling studies. 9 This cohort has also been used for exploring the integrated 
analysis of SPAG5 CNAs, transcript, and protein expression.  
B) Test cohort: Uppsala (n=249)  
The ANN modelling-based data mining approach and the clinicopathological 
significance of SPAG5 gene expression were tested in the Uppsala cohort 
composed of 315 women representing 65% of all breast cancersBCs resected in 
Uppsala County, Sweden (1987-1989) with a median follow-up of 126 months   (IQR 
119-134).  Gene expression data were available for only 249 patients. 10 
C) Validation cohorts: 
1) METABRIC (Molecular Taxonomy of Breast Cancer International 
Consortium) cohort (n=1980)  
The ANN modelling-based data mining approach and integrated SPAG5-CNA and 
SPAG5-trancript analysis was validated using the METABRIC cohort; a set of 1980 
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BCs with median follow-up 109 months (IQR 62-155).11   In this cohort, oestrogen 
receptor positive (ER-+positive) and/or lymph-node negative (LN-negative) patients 
did not receive adjuvant chemotherapy, whereas ER negative (ER-) and/or lymph-
node positive (LN+) -positive) patients received adjuvant chemotherapy. Additionally, 
none of the human epidermal growth factor receptor-2 (HER2) overexpression 
patients received trastuzumab. 
2) Untreated lymph-node negative BC cohorts:  
The prognostic significance of SPAG5-mRNA expression was assessed in three 
publically available datasets of LN-negative BC (n=684). These patients did not 
receive any adjuvant systemic therapy, thereby allowing the effect of SPAG5-
transcript on the natural history of the disease to be observed. These data sets were 
described in previous publications by Wang et al 12 (n=286), Desmedt et al 13 
(n=196), and Schmidt et al 14 (n=200).  The median follow up of each cohort is 
summarized in appendix p1-3.  
3) Multi-Centre Combined cohorts (MCC; n=5439) 
We evaluated the prognostic utility of SPAG5-mRNA expression in a large combined 
BC cohort which was sourced from 36 publically-available, global data sets (n=5439) 
using the online bc-GenExMiner program (http://bcgenex.centregauducheau.fr). 15   
A list of all the datasets, with references, is summarized in appendix p4-6. 
4) Nottingham Historical early stage BC cohort (Nottingham-HES-BC; n=1650)  
The clinicopathological significance and prognosis of SPAG5 protein expression was 
also validated in a cohort of BC (n=1650; age>71 years) 16 whose tissues were 
suitable for SPAG5 immunohistochemistry (IHC). These patients were diagnosed 
and treated uniformly between 1986 and 1999 at thein Nottingham City Hospital 
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(NCH), Nottingham, UK. Patients within the good prognosis group (Nottingham 
Prognostic Index (NPI) <3·4) did not receive systemic adjuvant therapy. Pre-
menopausal patients within the moderate and poor prognosis groups were 
candidates for CMF chemotherapy (cyclophosphamide 750 mg m−2, methotrexate 50 
mg m−2 and 5-fluorouracil 1 g m−2, on day 1 of a 21-day cycle.cyclophosphamide, 
methotrexate and 5-fluorouracil) chemotherapy. Conversely, postmenopausal ER+ -
positive patients with moderate or poor NPI were offered hormonal therapy, whereas 
ER-negative patients received CMF chemotherapy. Clinical data were maintained on 
a prospective basis with a median follow-up of 143 months   (IQR 114-174). 16.  The 
median follow up of subgroups is summarized in appendix p1-3. 
II) The clinical significance of SPAG5-protein and SPAG5-transcript expression 
in the context of currently used chemotherapy in BC  
In order to evaluate the value of SPAG5 transcript and protein expression as a 
biomarker in the context of current combination cytotoxic chemotherapy, we further 
evaluated the clinical significance of SPAG5 protein and transcript expression in 
adjuvant and neo-adjuvant chemotherapy settings.  
1. Nottingham early stage ER-negative BC adjuvant chemotherapy cohort 
(Nottingham-ER-negative ; n=697) 
To evaluate the survival benefit of SPAG5-protein expression, we analysed its 
expression in a consecutive series of 697 early stage ER-negative BC’s who had 
been diagnosed and managed at NCH between 1999 and 2007.  This series 
included: 1 ) 332 patientsThe ER-negative BC patients  of Nottingham historical early 
stage BC cohort (n=332) who were treated managed before 2000, who were and 
Formatted: Not Superscript/ Subscript
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treated  either with either no chemotherapy-naïve or adjuvant CMF, and 2) the new 
ER-negative early stage BC 365 patients (n=365) who were managed treated after 
2000, who and were received either no chemotherapy-naïve or received 
anthracycline-based adjuvant chemotherapy (AC-ACT). 1717 The median follow up of 
different treatment subgroups is summarized in appendix p1-3. 
2. Nottingham anthracycline based Neo-Adjuvant Chemotherapy cohort 
(Nottingham AC-Neo-ACT; n=200) 
The relationship between SPAG5-protein expression and response to chemotherapy 
was evaluated by investigating its expression in pair-matched pre-chemotherapy 
core biopsies and post-chemotherapy surgical specimens, from 200 female patients 
with locally-advanced primary BC (LAP-BC) (stage IIIA-C) that had been treated with 
anthracycline-based Neo-ACT (AC-Neo-ACT) 18 at NCH between 1996 and 2012.  
Sixty three percent of patients (127/200) received six cycles of an anthracycline-
based therapy (FEC: 5-fluorouracil (5-FU) 500 mg m−2, epirubicin 75–100 mg m−2, 
cyclophosphamide 500 mg m−2, on day 1 of a 21 day cycle), whereas 37% of 
patients received FEC plus Taxane (73/200). All patients underwent mastectomy or 
breast-conserving surgery and axillary dissection, followed by adjuvant radiation 
therapy. Patients with ER+ -positive BCs were offered 5 years of adjuvant endocrine 
therapy.  The median follow-up time was 67 months (IRQ 27-81). 
University of Texas MD Anderson Cancer Centre-Taxane/Anthracycline-based 
neo-adjuvant chemotherapy cohort (MDACC-T/AC-Neo-ACT; n=508) 
The relationship between SPAG5-transcript expression and response to 
chemotherapy was evaluated using MDACC-T/AC-Neo-ACT -cohort  in which 
Formatted: Font: Not Bold
15 
 
patients were selected for newly diagnosed ERBB2 (HER2- or HER2/neu) negative 
BC and treated with sequential taxane and anthracycline–based neo-adjuvant 
chemotherapy (then endocrine adjuvant therapy if ER+). -positive). Details of 
patients’ characteristics have been previously reported. 19 The median follow-up time 
was 38 months (IRQ 26-53). 
3. Multicentre phase II AC-Neo-ACT clinical trial cohort (NCT00455533; n=  
n=253) 
The relationship between SPAG5-transcript and the response to AC-Neo-ACT was 
validated using a randomised, open-label, multicentre, phase II clinical trial 
(NCT00455533) in which women with early stage BC (T2–3, N0–3, M0, tumour size 
2.·0 cm) have received AC-Neo-ACT regimens (cyclophosphamide plus doxorubicin 
(AC), followed by ixabepilone or paclitaxel).  Full details of the study design and the 
patient characteristics have been described previously. 20 Out of 295 patients 
enrolled into the trial, 253 patients had available gene expression data and pCR 
data.  
Procedures 
1- The ANN modelling-based data mining approach  
To identify factors that could drive proliferation and its associated features in BC, a 
number of factors that are directly and indirectly related to proliferation, defined as 
clinical class questions (e.g. histological-grade; mitotic index (MI); Ki67; TOP2A; 
KIF2C; BIRC5 and 5-year-survival), were analysed  by applying an ANN modelling-
based data mining approach in three gene expression array transcriptomic datasets, 
that included the ND, Uppsala and  METABRIC cohorts.  The ANNs have been 
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selected to data mine the clinical data sets identified in this study as they have 
previously been shown to be able to identify biomarkers, with high sensitivity and 
specificity that predict clinical features with excellent validity for unseen data sets. 6 
In additions, ANNs unlike conventional statistical approaches (such as hierarchical 
clustering, principal components analysis or linear regression) are not limited by 
linear functionality; this provides improved representation of biological features. The 
ranked orders of genes, produced in this way were compared across multiple 
proliferation related clinical class questions within a given dataset. The top 100 
ranked genes for predicting each clinical class question, based on minimum average 
route mean squared error, were compared and commonalities identified at the probe 
level. Further comparisons were then made for the same clinical class questions in 
the other datasets in order to determine a consensus list of gene probes across all of 
the features and data sets.  The strongest 100 integrated interactions were selected 
for visualisation in Cytoscape (Version 3.1.1, The Cytoscape Consortium; San-
Francisco, USA. 21   Further details of the ANN approach is presented in  appendix 
p7-810.  
2- SPAG5 CNAs 
CNAs at the SPAG5 locus on chromosome 17q11.2 were retrieved from both high 
resolution (<100 kb) oligonucleotide microarrays, comparative genomic hybridization 
(aCGH; ND cohort), and Affymetrix SNP 6.0 platform profiling (METBRIC cohort) that 
has been previously described by our group. 9, 11 The oligonucleotide arrays data can 
be access at (http://www.ncbi.nlm.nih.gov/geo/; series accession number-GSE8757) 
whereas SNP data are available through the European Genotype Archive 
(http://www.ebi.ac.uk/ega/page.php) under accession Number: EGAS00000000082). 
An additional analysis considered a set of 85 individuals of European ancestry for 
Formatted: Justified
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whom genotyping was performed on non-cancerous tissue and gene expression 
values from matched normal tissue were available. 11 
3- SPAG5 and MKi67 gene expression 
SPAG5 and MKi67 mRNA expression data were retrieved and analysed in the 
following cohorts:- ND [using Agilent gene expression arrays at 
(http://www.ebi.ac.uk/miamexpress/ with accession number E-TABM-576), Uppsala 
[using Affymetrix U133A&B Gene-Chips microarray profiling data at 
(http://www.ncbi.nlm.nih.gov/geo/) with series accession number (GSE4922)], and 
METABRIC [using Illumina HT-12 v3 platform (Bead Arrays) 11 data at 
(http://www.ebi.ac.uk/ega/page.php) under accession Number 
(EGAS00000000082)].    In addition, the SPAG5 and MKi67 mRNA expression data 
has been retrieved for three publically available datasets of LN-negative BC  in which 
patients did not receive any adjuvant systemic therapy: Wang et al12 (accession 
number: GSE2034; n=286), Desmedt et al13 (accession number: GSE7390; n=196), 
and Schmidt et al14 (accession number: GSE11121; n=200).  For the MCC cohort, 
details of the gene expression data processing, normalization and the statistical tests 
have been described previously. 15 In this cohort, gene expression data  were 
converted to a common scale (median equal to 0 and standard deviation equal to 1) 
in order to merge all of the studies data and create combined cohorts (for more 
details see appendix p8). 22 The gene expression data for the MDACC-T/AC-Neo-
ACT cohort and the phase II clinical trial (NCT00455533) has been downloaded 
using accession number GSE25066 and GSE41998; respectively. 
4- Immunohistochemistry (IHC) staining of SPAG5 and Ki67  Formatted: Space After:  0 pt
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The ND, Nottingham-HES-BC, Nottingham-ER-negative and Nottingham-AC-Neo-
ACT cohorts were IHC profiled for SPAG5, Ki67 and other biological parameters..  
TTissue microarrays (TMAs), as described in detail in appendix p9p8-11 12 have 
been used for IHC profiling of SPAG5 in all cohorts except in Nottingham-AC-Neo-
ACT where full-face sections of core biopsies have been used.    
Determination of the cut-offs 
The median in each cohort was used as cut-off between low and high expression 
gene/protein expression 
Outcomes: 
The clinicopathological and biomarkers associations: The clinicopathological 
and molecular characteristics of SPAG5 transcript were determined in the Uppsala, 
METABRIC, MCC and MDACC-T/AC-Neo-ACT cohorts.  SPAG5–CNA moleculear-
/pathological associations were analysed in METABRIC cohort.   The associations 
between SPAG5 protein expression and clinicopathological parameters, as well as 
prognostic biomarkers, were analysed in the Nottingham-HES-BC, the Nottingham-
ER-negative and the Nottingham-AC-Neo-ACT cohorts. The clinicopathological 
parameters including mainly: tumour size, lymph node stage, histological grade, 
genomic grade index (GGI), TP53 mutation, intrinsic molecular subclasses, PAM50, 
HER2 amplification/overexpression, hormone receptors, Ki67, mitotic index, Bcl2 
and other biological biomarkers.   
Breast cancer specific survival (BCSS): SPAG5 transcript expression association 
with BCSS was explored in the ND cohort and validated in Uppsala, METABRIC and 
the untreated LN-negative Desmedt et al cohorts.  SPAG5-CNAs association with 
BCSS was tested in METABRIC cohort whereas the association between SPAG5 
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protein expression and BCSS was analysed in the ND cohort, Nottingham-HES-BC 
cohort and Nottingham-ER-negative cohorts.   
Disease free survival (DFS): SPAG5 transcript expression association with DFS 
was examined in untreated LN-negative cohorts (Wang et al and Desmedt et al), 
MCC and Nottingham-AC-Neo-ACT cohorts.   
Distant relapse free survival (DRFS):  SPAG5 transcript expression association 
with DRFS were was determined in untreated LN-negative Schmidt et al and 
Desmedt et al cohorts.  Furthermore, to teste SPAG5 transcript expression as a 
biomarker for outcome after neo-adjuvant combination cytotoxic chemotherapy, 
thereir associations with DRFS have has been analysed in the MDACC-T/AC-Neo-
ACT cohort.  
Pathological complete response (pCR) and residual cancer burden (RCB): To 
evaluate SPAG5 protein and transcript expression as a predictor predictive 
biomarker for response to combination cytotoxic chemotherapy, thereir association 
with both pCR and RCB 23 have been analysed in the Nottingham-AC-Neo-ACT,  the 
MDACC-T/AC-Neo-ACT, and the phase II AC-Neo-ACT clinical trial cohort 
(NCT00455533); respectively. The pCR was defined as the absence of any residual 
invasive carcinoma at both the primary site and in axillary LNs. 
The clinicopathological and biomarkers associations: The clinicopathological 
and molecular characteristics of SPAG5 transcript were determined in the Uppsala, 
METABRIC, MCC and MDACC-T/AC-Neo-ACT cohorts.  SPAG5–CNA molecule-
pathological associations were analysed in METABRIC cohort.   The associations 
between SPAG5 protein expression and clinicopathological parameters, as well as 
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prognostic biomarkers, were analysed in the Nottingham-HES-BC, the Nottingham-
ER- and the Nottingham-AC-Neo-ACT cohorts.  
Statistical analysis were performed using STATISTICA (Stat Soft Ltd, Tulsa, USA) 
and SPSS (version 17, Chicago, USA) by the authors (TAF, GRB) who were blinded 
to the clinical data. The Chi-square test was used for testing associations between 
categorical variables, and a multivariable Cox model was fitted to the data using 
survival time as the endpoint.  All tests were two-sided with a 95% CI and a p value 
of <0·05 was considered to be indicative of statistical significance. Multiple-testing 
correction was applied to all p-values using the Bonferroni method. The range of 
corrections were (5 - 48,803) across the different analyses.  Gene-dosage levels to 
gene expression were evaluated using the Jonckheere's trend test in order to 
evaluate the significance of the correlation between CNAs and aberrant gene-
expression. Pearson correlations between mRNA expression log intensity values 
and SPAG5 protein expression (H-score) were used to determine whether mRNA 
expression levels correlated with protein levels. See appendix p12 p8-9 for details. 
Power analysis and false discovery correction 
Power analysis for the ANN model was conducted using a logistic regression power 
model (of which ANNs are an extension with a greater power), using G*Power 3.1.9 
software (Heinrich Heine University of Dusseldorf, Dusseldorf, Germany). 24 To 
determine sample size, an alpha of 0.·05, a power of 0.·80, an effect size (odd ratio 
= 1.·72) and two-tailed test, were chosen for binary questions or classes (e.g., low 
vs., high expression).   Based on the assumptions of the power model, the desired 
sample size is 88 (44  per in each low and high class). The use of a Monti Carlo 
cross validation (MCCV) strategy was further used to prevent false discovery, over-
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fitting and to increase the power of the algorithm used (see appendix p7 for detail). 
By repeatedly testing on an unseen data set and stopping accordingly, over-fitting is 
prevented. False discovery is further reduced in this study by parallel analysis on 
multiple questions in multiple datasets.  With each separate analysis reducing the 
probability that a gene could be discovered by random chance, and yet still be a 
common result across multiple analyses, of separate datasets.  
The probability (p) of the 30 genes occurring as common in the top 100 out of the 
whole expression array for the three cohorts for a minimum of 4 proliferation-related 
factors = 1·43x10-31 (see the calculation in appendix p8p7).   
A retrospective power analysis was conducted to determine the confidence in the 
calculated hazard ratio and associated p value for 10 year survival and to ascertain 
how applicable the result would be to a global population.   
For the METABRIC cohort - transcript expression analysis, a power model using a 
two-sided log-rank test with an overall sample size of 1950 subjects (970 in the high 
SPAG5-transcript (+) groups) achieved a power in excess of ≥99·9% to detect a 
hazard ratio (HR) of 1·68, when the proportion surviving to 10 years in the SPAG5+ 
and SPAG5- are 78% and 66% respectively. The p value in this case was <0.·0001.   
In the case of the untreated LN-negative-BC cohorts: Wang et al (n=286; 143 cases 
with SPAG5+), Schmitt et al (n=200; 100 cases with SPAG5+), and Desmedt et al 
(n=198; 99 cases with SPAG5+), the retrospective power of each to detect HRs of 
1·3, 1·4, and 1·99 at ten years was 82%, 84%, and 98%; respectively, with p<0·05 . 
As a combined cohort, with an overall sample size of 5439 (2711 in SPAG5+), a 
≥99·9% power to detect a HR of 1·68, with p-value <0.·001, was achieved.  
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For the Nottingham HES BC cohort, with an overall sample size of 1342 subjects 
(273 cases in the SPAG5-protein+ subgroup), a 99·0% power to detect a HR of 1·86 
is achieved with p-value <0·01, when the proportion surviving in the SPAG5+ 
subgroup at ten years is 63%.   
Results 
Our ANN analysis in three cohorts (ND, Uppsala and METABRIC cohorts) identified 
the top 100 ranked genes that predict most of the proliferation-related features ( 
appendix p13-27). We chose to further study the clinicopathological implication of 
SPAG5 because it was found to be among 30 common gene-probes that were 
predictive across most of the proliferation features and datasets, and it features 
prominently in the interactome  maps (Figure appendix p25-27).  In addition, in a 
small set of BC, investigators found that SPAG5 transcript was a mong few genes 
that were associated with poor prognosis in ER-positive BC. 25   Because Ki67 has 
been used by many investigators as a marker for proliferation when choosing the 
appropriate systemic-treatment, subsequently we chose to be used it as a control in 
our study.   
Gain/amplification at the SPAG5 locus (17q11·2) occurred in 16% (26/171) and 
10·4% (206/1980) (10·4%) of BC, in the ND and METABRIC cohorts respectively. 
SPAG5-gain/amplificationCNA was more common in high-grade, PAM50-HER2, and 
PAM50-LumB.  A strong correlation between SPAG5-CNA and SPAG5-transcript 
expression was apparent (ND cohort: Spearman-correlation r=0.·81; Bonferroni-
adjusted-p=0·010) and METABRIC: Spearman-correlation r=0·87; Bonferroni-
adjusted-p<0·0001). ER-negative and ER-positive BC exhibited a higher level of 
SPAG5-transcript (correlation-coefficient=0·19; Bonferroni-adjusted-p<0·0001 and 
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correlation-coefficient=0·37; Bonferroni-adjusted-p<0·0001; respectively) compared 
to normal individuals (n=85). However, the level of SPAG5-transcripts in ER-negative 
disease was higher than that in ER-positive disease (correlation-coefficient=0·18; 
Bonferroni-adjusted-p<0·0001). Furthermore, the PAM50-LumB, PAM50-Basal and 
PAM50-HER2+ BC-subclasses exhibited higher levels of SPAG5-transcripts than 
PAM-50-normal-like,  and  PAM-50-PAM50-Lum-A disease, and normal tissue (all-
adjusted-p<0·0001; Figure appendix p28).   
As a continuous and categorical variable, compared to low SPAG5-transcript 
expression, high SPAG5-transcript expression level (>median) was associated with 
high-grade TP53- mutation, and HER2 gain/amplification. In the METABRIC study, 
10-novel-prognostic biological subgroups have been identified by the joint clustering 
of CNA and gene expression data (integrative-clusters (intClust)). 11 Herein, SPAG5-
gain/amplification was shown to be associated with intClust-1, 5, and 6 (all-
p<0·0001) whereas SPAG5-overexpression was associated with intClust-1, 5, 9, and 
10; appendix p29-32. Furthermore, high SPAG5-transcript expression (>median)+ 
was associated with other molecular parameter/indices/subclasses that predict 
higher probability of response to Neo-ACT: RCB-0/I, 23 genomic-chemo-sensitivity 
predictor, 19  genomic-excellent-pathologic-response predictor, 19 96-gene-genomic-
grade index (GGI), 26 diagonal linear discrimination analysis of 30-gene (DLDA30) 
signature (DLDA30), 27 and PAM-50-gene signature 28 (all p<0·0001, appendix 
p30p33). 
Additionally, there was a strong correlation between SPAG5-transcript and SPAG5-
protein expression (Pearson-correlation (r=0·75); Bonferroni-adjusted-p=0·001).  In 
the Nottingham-HES-BC cohort, 20%272/1368 (272/136820%) of patients showed 
high SPAG5-protein+ (H-score≥10) that was associated with aggressive phenotypes 
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including HER2+ -overexpression (p=0·030), Luminal-B (ER-positive+/HER-
negative/high-Ki67), an absence of hormone receptors, and TP53-mutation 
(appendix p34-3637). In the Nottingham-ER-negative cohort, high SPAG5-protein+ 
(H-score>10) was observed in 51%355/697 (355/69751%) and was associated with 
lympho-vascular-invasion, high-grade, and high-ki67 (all p<0·0001; appendix 
p37p38-3941).   In Nottingham AC-Neo-ACT locally advanced BC cohort, high 
SPAG5-protein+ (H-score>10) was observed in 25·0% 50/200 (50/200) 25·0%) of 
pre-chemotherapy core biopsies and was associated with high-grade, Luminal-B 
(ER+/-positive/HER2-negative/high Ki67), ER-/-negative/HER-negative, and TP53-
mutation (all adjusted p<0·0001).  Among different cohorts neither SPAG5 transcript 
nor protein was associated with LN- stage or disease clinical stage.  
SPAG5-gain/amplification was associated with shorter BCSS than SPAG5-
normal/loss in all patients (HR (CI 95%):1·50 (1·18-1·92); p=90·00166*x10-4) and the 
ER-positive+ subgroup (HR (CI 95%): 1·55 (1·18-2·04); p=20·000201*x10-4), but not 
in ER-negative  tumours (HR (CI 95%): 1·58 (0·97-2·56), p=60·065*x10-2) (Fig.2A-
C); METABRIC cohort.   
As continuous variables, high SPAG5-transcript expression levels was associated 
with shorter BCSS than low SPAG5-transcript [ND cohort: (HR (CI 95%):1·50 (0·98-
2·32); p=60·065*x10-2), Uppsala cohort: (HR (CI 95%): 1·99 (1·44-2·76); p<0·0001) 
and METBRIC cohort: (HR (CI 95%): 1·89 (1·55-2·31); p<0·0001)].  As a categorical 
variable high SPAG5-transcript+ (>median), was associated with shorter BCSS than 
low SPAG5-transcript [Uppsala: (HR (CI 95%): 1·98 (1·29-3·04); p=20·00200*x10-3), 
and METABRIC: (HR (CI 95%): 1·68 (1·40-2·01); p<0·0001, Fig2D).  High SPAG5-
transcript overexpression was associated with shorter BCSS than low SPAG5-
transcript in ER-positive sub-groups but not in ER-negative tumours (Fig.2E-F).   
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Also, in the low-risk BC (NPI≤3·4), LN-negative, as well as LN-positive (METABRIC), 
high SPAG5 transcript was associated with shorter BCSS than low SPAG5 transcript 
(Figure appendix 4042). In Uppsala cohort with 249 cases (124 in the high SPAG5 
transcript group) achieved a power of 83% to detect a hazard ratio (HR) of 1·98 , 
when the 10 years survival rate for high and low SPAG5 transcript are 53% and 
71%; respectively with p value <0.050.  Similarly for the METABRIC cohort transcript 
expression analysis, a power model using a two-sided log-rank test with an overall 
sample size of 1950 subjects (970 in the high SPAG5-transcript groups) achieved a 
power in excess of ≥99·9% to detect a hazard ratio (HR) of 1·68, when the 
proportion surviving (BCSS) to 10 years in the high SPAG5 and low SPAG5 are 78% 
and 66%; respectively, with p <0·0001.   
In untreated LN-negative cohorts high SPAG5 transcript (>median) was associated 
with shorter DSF, DRFS and BCSS than low SPAG5 transcript (Fig.2G-I].  In the 
untreated LN-negative-BC cohorts: Wang et al (n=286; 143 cases with high SPAG5), 
Schmitt et al (n=200; 100 cases with high SPAG5), and Desmedt et al (n=198; 99 
cases with high SPAG5), the retrospective power of each to detect HRs of 1·3, 1·4, 
and 1·99 at ten year of for DFS, DRFS and BCSS was 82%, 84%, and 98%; 
respectively, with p<0·050.   
In the Uppsala cohort multivariable Cox regression analysis including patient age, 
LN-stage, tumour-size, genomic-grade index (GGI), ER status, and MKi67-transcript, 
revealed that high SPAG5-transcript+ and LN-stages were independently associated 
with increased-risk of death (Table-1A).  Similarly in the METABRIC cohort, a 
multivariable Cox regression model which included patient age, tumour size, grade, 
LN-stage, HER2, ER, PR, hormone-therapy, and chemotherapy, demonstrated that 
high SPAG5-transcript+ was independently associated with shorter BCSS (Table-
Formatted: Font: Italic
Formatted: Font: Italic
Formatted: Font: Italic
Formatted: Font: Italic
Formatted: Font: Italic
26 
 
1B).  Furthermore, multivariable Cox regression models showed that SPAG5-
transcript+ was associated with clinical outcome independently of both PAM50 and 
intClust prognostic subclasses (Table 1C-D).  Furthermore, in the untreated LN-
negative Desmedt et al cohort, high SPAG5-transcript+ was associated with shorter 
BCSS after adjustment for ER status and other prognostic signatures/indices such 
as 76-gene prognostic signature (Veridex)13, Adjuvant-Online (AOL) and the 
Nottingham Prognostic Index (Table 1-E). 
In the MCC cohort high SPAG5-transcript (>median) was associated with increased 
risk of relapse compared to low SPAG5-transcript expression in all patients and LN-
negative, LN-positive, and ER-positive BC subgroups, but not in the ER-negative-
subgroup (Figure appendix p43).  In MCC, with an overall sample size of 5439 (2711 
in high SPAG5), a ≥99·9% power to detect a HR of 1·68 for DFS, with p-value 
<0·0010, was achieved.  In the MCC cohort, multivariable Cox regression models 
confirmed that the high SPAG5-ranscript is an independent poor prognostic factor 
after controlling for NPI (HR (CI 95%): 1·19 (1·09-1·30); p=0·00020), AOL (HR (CI 
95%): 1·18 (1·03-1·35); p=0·017), and 72-proliferation-gene-signature 29 (HR (CI 
95%): 1·18 (1·10-1·27); p<0·0001). Univariate analysis showed that high MKi67 
transcript expression was associated with a higher risk of relapse compared to low 
MKi67 expression. However, multivariable Cox regression models revealed that 
MKi67 transcript expression was not an independent prognostic factor for BC after 
controlling for NPI (HR (CI 95%): 1·09 (1·00-1·20); p=0·060) and AOL (HR (CI 95%): 
0·93 (0·83-1·05); p=0·26). 
Similarly high SPAG5-protein+ expression was associated with shorter BCSS than 
low SPAG5-protien expression (ND: HR (CI 95%): 1·06 (1·02-1·09), p=0·0010, and 
Nottingham-HES-BC cohorts: HR (CI 95%): 1·68 (1·32-2·12), p<0·0001; Fig.3A]. 
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High SPAG5-protein+ was also associated with increased-risk of death in ER+ -
positive subgroups (Fig.3B), but not in ER- negative subgroups (Fig.3C).  In the low-
risk (NPI<3·4), LN-negative, as well as LN-positive subgroups SPAG5 protein was 
associated with shorter BCSS (Figure appendix p 40p44), and.  For the ND and 
Nottingham HES BC cohort, with an overall sample size of 128 and 1342 subjects 
(24 and 273 cases in the SPAG5-protein+ subgroups), 80% and 99·0% powers to 
detect a HR of 1.10 and 1·68 is achieved with p-value <0·05, when the proportion 
surviving in the high SPAG5 subgroup at ten year of BCSS is 60% and 63%; 
respectively.   
Multivariable Cox regression analysis reveals that high SPAG5-protein+ was 
independently associated with a poorer BCSS at 10 years, after adjustment for 
adjuvant hormone-therapy and chemotherapy- adjuvant- chemotherapytherapies, 
grade, size, LN-stage, HE2, ER, PR, age, Ki67 and interaction-terms (SPAG5* 
chemotherapy and SPAG5* hormone-therapy); Table 1F.   
In the Nottingham-ER-negative cohort, high SPAG5-protein+ was associated with 
decreased risk of death from BC (HR (95% CI): 0·85 (0·78-0·94); p=0·0010) (Fig.3D) 
compared to low SPAG5-protein expression. However, a subgroup analysis of 
adjuvant-chemotherapy-naïve cases showed that patients with high and low SPAG5-
protein (+) and (-) BCexpression exhibited similar BCSS (HR (95% CI): 0·90 (0·63-
1·27); p=0·54), whereas in the subgroup that received adjuvant-chemotherapy; high 
SPAG5+ -protein exhibited lower risk of death (HR(95% CI): 0·41 (0·26-0·64); 
p=<0·00018·0*10-5) compared to low SPAG5-protein level, (Figure appendix 
p41p45).  In ER-negative BC with high SPAG5-protein+, administration of 
anthracycline-ACT had reduced the risk of death by 60% compared to 
chemotherapy-naive (HR (95% CI): 0·37 (0·20-0·60); p=0·0010) (Fig.3E). Meanwhile 
28 
 
administration of anthracycline-ACT had no impact on tumours with ER-negative /low 
SPAG5-protein- BC phenotype  (Fig.3F). A multivariable Cox regression model 
confirms that SPAG5 was a predictive marker and that the interaction-term between 
SPAG5-protein and the administration of anthracycline-based adjuvant 
chemotherapy was a significant predictor of for BCSS (Table-1G). 
In the MCC cohort SPAG5-transcript+ was associated with increased risk of relapse 
in all patients and LN-negative, LN-positive, and ER-positive BC subgroups, but not 
in the ER-negative-subgroup (appendix p42).  In the MCC cohort, multivariable Cox 
regression models confirmed that the SPAG5-ranscript+ is an independent poor 
prognostic factor after controlling for NPI (HR (CI 95%): 1·19 (1·09-1·30); adjusted-
p=2·0*x10-4), AOL (HR (CI 95%): 1·18 (1·03-1·35); adjusted-p=1·71*x10-2), and 72-
proliferation-gene-signature28 (HR (CI 95%): 1·18 (1·10-1·27); adjusted-p<0·0001). 
Univariate analysis showed that high MKi67 transcript expression was associated 
with a higher risk of relapse. However, multivariable Cox regression models revealed 
that MKi67 transcript expression was not an independent prognostic factor for BC 
after controlling for NPI (HR (CI 95%): 1·09 (1·00-1·20); adjusted- p=0·06·0x10-2) 
and AOL (HR (CI 95%): 0·93 (0·83-1·05); adjusted- p=0·2·6x10-1). 
In the MDACC-T/AC-Neo-ACT cohort, after receiving combination cytotoxic 
chemotherapy,   there was a marginally shorter DRFS in those patients with high 
SPAG5-transcript+ tumours compared to low SPAG5-transcript(HR (CI 95%): 1·3 
(0·92-1·95); p=0·12; appendix p43). In those patients that did not achieve pCR, high 
SPAG5-transcript+ was significantly associated with shorter DRFS than those with 
low SPAG5-transcript (HR (CI 95%): 1·74 (1·17-2·52); p=0·0070; appendix p43p46). 
A multivariable Cox regression analysis which included other prognostic factors for 
chemotherapy, namely genomic-chemo-sensitivity predictor, GGI, DLDA30, PAM-50-
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genes, American joint committee of cancer (AJCC) -stages, and MKi67 transcript, 
revealed that high SPAG5 was independently associated with decreased risk of 
distant relapse after receiving Neo-ACT (HR (CI 95%): 0·68 (0·48-0·97); 
p=70·0070*x10-3; Table1H). 
To validate our previous observation, we investigated the relationship of SPAG5 
transcript expression and response to combination cytotoxic chemotherapy in the 
MDACC-T/AC-Neo-ACT cohort (n=508) in which 488 cases had pCR data were 
available.  Of them, 20%99/488 (99/48820%) achieved pCR.  As a continuous 
variable, high SPAG5-transcript levels were associated with higher pCR compared to 
low SPAG5-transcript (OR (CI 95%): 2·6 (1·8-3·9); p<0·0001).  As a categorical 
variable, high SPAG5-transcript+ (>median) was association with higher pCR; 29% 
(70/246) (29%) vs 12% 29/242 (29/24212%) for low SPAG5-transcript- (OR (95% 
CI): 2·90 (1·80-4·70), p=<0·00016·0*10-6). Multivariable logistic regression analysis 
including parameter/indices/subclasses that associated with higher pCR as well as: 
AJCC clinical stage, histological grade, ER, PR, and patient age, demonstrated that 
high SPAG5-transcript+ was an independent predictor for higher pCR (Table-2A).   
We further validated our results in a multicentre phase II anthracycline-based-Neo-
ACT clinical trial cohort (NCT00455533) 20 in which 27% (69/253) and 34% (86/253) 
of patients achieved pCR and RCB-0/RCB-1 rates, respectively.  As a continuous 
variable, SPAG5-transcript expression was associated with a marginally higher 
incidence of pCR and RCB-0/RCB-1 ((OR (CI 95%): 1·33 (0·98-1·79); p=0·065) and 
(OR (CI 95%): 1·29 (0·98-1·71); p=70·075*x10-2); respectively).  Using the median to 
categorize SPAG5-transcript expression into (high+) and (-); (low); high SPAG5-
transcript+ was associated with higher pCR and RCB-0/RCB-1 rates ((OR (CI 95%): 
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1·99 (1·13-3·45); p=10·016*x10-2) and (OR (CI 95%): 1.97 (1·16-3·34); 
p=10·010*x10-2), respectively) compared to low SPAG5-transcript. In a multivariable 
logistic regression model which included ER, PR,; Her2, tumour size, menopausal 
status, and MKi67, and SPAG5 transcript expression, SPAG5-transcript was 
significantly associated with RCB-0/RCB-1 (Table 2B). 
Similar to transcriptomic findings, patients with high SPAG5-protein (H-score>10) + 
disease prior to chemotherapy, who received AC-Neo-ACT, exhibited similar 5-year 
DFS following surgery (HR (95% CI): 1·1 (0·90-1·30); p=0·40) to those with low 
SPAG5-protein- disease (appendix p43).  Importantly, patients with high SPAG5-
protein+ BC expression in the residual tumour specimen after receiving AC-Neo-ACT 
were at a higher risk of relapse (HR (95% CI): 2·2 (1·2-4·2); p=0·010) compared to 
those with low SPAG5-protein residual tumours– BC, at the 5-year follow-up (Figure 
appendix p43p46). In the Nottingham-AC-Neo-ACT cohort, 14·5% (29/200) of 
patients had achieved pCR and 40%20/50 (20/5040%) of patients with high SPAG5-
protein+ BC achieved pCR compared to 6% (9/150) (6%) of those with low SPAG5-
protein- disease (OR (CI 95%): 10·8 (4·5-26·29); p<0·0001; appendix 
p43)Supplementary-Fig.5A). Furthermore, 37%18/49 (18/4937%) of BC that 
exhibited high SPAG5-protein+ disease became negative for SPAG5-protein after 
receiving AC-Neo-ACT (McNemar-test; p=40·0040*x10-3).  Multivariable logistic 
regression analysis revealed that high SPAG5-protein+ was an independent 
predictor of for pCR, whereas Ki67 was not, after controlling for age, taxane, grade, 
AJCC stage, ER, HER2, Ki67, Bcl2, and TOP2A (Table-2C).   
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Discussion 
To our knowledge this is the first multi-dimensional study to report on the clinico-
pathological utilities of SPAG5 in BC in more than 10,000 patients. Our findings 
suggest that: 1) Amplification/gain of the SPAG5 locus at Ch17q11·2 occurred in 10-
20% of BC, 2) The SPAG5-gene-CNA and its transcript and protein were associated 
with poor clinical outcome and adverse clinicopathological features, including TP53-
mutation, PAM50-LumB, and PAM50-Her2, 3) Both SPAG5 transcript+ and protein+ 
are independent predictors for response to chemotherapy.  
Recent advances in molecular biology have generated a huge amount of data, which 
has then been used to generate multigene-profiles for guiding chemotherapy 
treatment. Unfortunately, almost all of these approaches face common issues such 
as insufficiently high levels of evidence, the over-fitting of computational models, 
false discovery rates, 30 and the lack of a potential biological mechanism to support 
their use as predictors of therapeutic response. Furthermore, they do not offer a 
significant improvement in predictive accuracy over the well-established pathological 
parameters or the cheaper, conventional immunohistochemistry approach, and may 
not be available for logistical or financial reasons. 31 In fact, the majority of the 
prognostic power of these assays comes from genes that are related to cell 
proliferation. The data presented herein are significant as the prognostic and 
predictive capacities of SPAG5 have been shown to be independent of many of 
these multigene tests and Ki67. Furthermore, our previous integrated network 
inference bioinformatics analysis has revealed that MKi67 was less influential on 
other proliferation factors, and lacked the centrality of other probes.   
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In agreement with the results of data mining the Oncomine-microarray database, we 
found BC, like most human cancers, exhibited a higher level of SPAG5-transcript 
expression compared to normal tissue (appendix 4447-4953), which in turn is 
associated with poor clinical outcome (appendix 5054-526), especially in ER+ -
positive BC. 25 In agreement with a previous study, we have reported a high level of 
Ch17q11·2 amplifications in HER2+ -overexpression and ER+ -positive BC, 32 which 
is the locus of SPAG5. Recently, duplication of CEP17 has been proposed as a 
marker of chromosomal instability, spindle assembly checkpoint deregulation, and it 
has been linked to anthracycline-sensitivity in vitro and to clinical outcome of AC-
ACT. 33 Likewise, given that SPAG5 has an essential role in the progression of the 
cell cycle during the mitotic phase, SPAG5 dysregulation could contribute to 
chromosome instability and aneuploidy, both of which are hallmarks of malignant 
cells and could confer vulnerability on the cancer cell. Given that drugs such as the 
anthracyclines and taxanestaxane, which interfere with the normal progression of 
mitosis, belong to the most successful chemotherapeutic compounds that are 
currently used for anti-cancer treatment, SPAG5 could be a molecular target on 
which the development of “next generation anti-mitotic drugs” could be based.  
Recent studies in cervical cancer 34, 35 reported SPAG5 to be up-regulated, and 
demonstrated that the down-regulation of SPAG5 inhibited cell proliferation/growth, 
increased apoptosis and hindered cell migration and invasion. 35 Furthermore, it is 
possible that “anti-SPAG5 agents” could sensitize resistant BC cells to current 
treatment regimens.   
The potential clinical significance of our results primarily relates to the identification 
of BC patients who are likely to benefit from anthracycline-based chemotherapy. 
Validating our results in a randomized-prospective Neo-ACT trial would allow 
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patients whose tumour response would be poor to be spared from enduring the 
unnecessary risk of cardiac toxicity, when other more effective agents can be used. 
Although the mechanism linking SPAG5+ and response to anthracycline is unknown 
and further investigation is warranted, it could be due to the accumulation of DNA 
damage, abnormal mitoses, and subsequent mitotic catastrophe.36  
In summary, our findings have the potential to introduce an accurate predictive 
biomarker for chemotherapy response, which would facilitate the effective tailoring of 
BC treatment. This work may lead to the development of novel therapeutic strategies 
for treating a subtype of BC, thereby increasing the chance of cure from BC.  
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AC = anthracycline combination 
AC-ACT = anthracycline combination adjuvant chemotherapy 
ACT = adjuvant Taxane chemotherapy (Docetaxel 75 to 100mgm-2 every 3 weeks, 
for 3 weeks) 
ANN = artificial neural network 
AOL = Adjuvant-Online 
AR = androgen receptor 
ASCO = American society of clinical oncology 
BC = breast cancer 
BCSS = breast cancer -specific survival 
CAP = college of American pathologists 
CI = confidence interval 
CNA = copy number aberrations 
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g m−2, on day 1 of a 21-day cycle. 
DFS = disease-free survival 
DM = distant metastasis  
DRFS = distant metastasis-free survival 
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ER = oestrogen receptor  
FEC/FAC = 5-Fluorouracil (5-FU) 500 mg m−2, Epirubicin 75–100 mg m−2, 
Cyclophosphamide 500 mg m−2, on day 1 of a 21-day cycle. 
FFPE = formalin-fixed paraffin embedded 
HER2 = human epidermal growth factor receptor 2 
HR = hazard ratio 
HPA = human protein atlas 
IHC = immunohistochemistry 
LAP-BC = locally-advanced primary breast cancer 
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MDACC-T/AC-Neo-ACT = University of Texas MD Anderson Cancer Centre-
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MCC = Multicentre combined cohort 
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Neo-ACT = neo-adjuvant chemotherapy 
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Nottingham-HES-BC = Nottingham historical early-stage-primary BC cohort 
NPI = Nottingham prognostic index 
NT = Nottingham series 
pCR = pathological complete response 
PR = progesterone receptor 
TMA = tissue microarray 
TNBC = triple negative breast cancer 
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Tables 
Table-1: Multivariable Cox regression models analysis in different breast cancer 
cohorts. 
 
A. Multivariable Cox regression model analysis for breast cancer specific survival 
in the Uppsala test cohort (SPAG5 transcript) (n=249) 
Variables HR 95·0% CI P value 
Lower Upper 
SPAG5 mRNA (high) 1·62 1·03 2·53 30·036*x1
0
-2
* 
MKI67 mRNA (high) 0.991 0.486 1.71 70·77x10
-1
 
Lymph node status (positive) 1·61 1·01 2·57 50·050*x10
-2 
96-gene genomic grade index (GGI) 
26 
 
G1 
G2a 
G2b 
G3 
 
 
1 
0·94 
1·77 
1·73 
 
 
 
0·50 
0·82 
0·76 
 
 
 
1·79 
3·96 
3·97 
30·34x10
-1
 
Age at diagnosis** 1·01 0·99 1·03 10·16x10
-
1
 
Tumour size (continuous) (mm) 1·09 0·95 1·24 20·21x10
-
1 
Oestrogen receptor (positive) 1·43 0·76 2·71 20·27x10
-
1
 
TP53 mutation 1·07 0·62 1·86 80·80x10
-
1
 
B. Multivariable Cox regression model (1) analysis for breast cancer specific 
survival in the METABRIC cohort (SPAG5 transcript) (n=1980) 
SPAG5 mRNA (high) 1·27 1·02 1·58 30·034*x1
0
-2
* 
Lymph node (LN) stage 
Negative 
1-3 positive LNs 
>3 positive LNs 
 
1·00 
1·68 
3·42 
 
 
1·31 
2·59 
 
 
2·16 
4.52 
<0·0001* 
Histologic grade 
Low 
Intermediate 
High 
 
1·00 
1·79 
2·05 
 
 
1·08 
1·23 
 
 
2·95 
3·39 
10·017*x1
0
-2
* 
Size 1·01 1.007 1·015 <0·0001* 
Age at diagnosis** 1·01 1·002 1·02 10·015*x1
0
-2
* 
HER2 1·50 1·18 1·91 10·0010*0 
x10
-3
* 
Progesterone receptor (positive) 0·77 0·62 0·96 20·020*x1
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0
-2
* 
Oestrogen receptor (positive) 1·06 0·78 1·45 70·70x10
-
1
 
Hormone therapy 1·23 0·82 1·02 10·12x10
-
1
 
Chemotherapy 1·31 0·96 1·78 90·090x10
-2
 
Hormone therapy*SPAG5 0·62 0·41 0·93 20·021*x1
0
-2
* 
Chemotherapy*SPAG5 0·84 0·55 1·28 40·42x10
-
1
 
C. Multivariable Cox regression model (2) analysis for breast cancer specific 
survival in the METABRIC cohort (SPAG5 transcript) (n=1980) 
SPAG5 mRNA (high) 1·31 1·04 1·65 20·020*x10
-2
* 
PAM-50 Molecular subclasses 
28 
PAM50-LumA 
PAM50-LumB 
PAM50-HER2 
PAM50-Basallike 
PAM50-Normal 
 
1 
2·13 
2·34 
1·89 
1·45 
 
 
1·62 
1·72 
1·38 
1·01 
 
 
2·80 
3·18 
2·59 
2·08 
<0·0001* 
 
Hormone therapy 1·31 1·06 1·60 10·010*x10
-2
* 
Chemotherapy 1·31 1·66 2·59 <0·0001* 
Hormone therapy*SPAG5 0·57 0·38 0·84 50·0050*x1
0
-3
* 
Chemotherapy*SPAG5 1·18 0·78 1·78 40·43x10
-1
 
D. Multivariable Cox regression model (3) analysis for breast cancer specific 
survival in METABRIC cohort (SPAG5 transcript) (n=1980) 
SPAG5 mRNA (high) 1·33 1·06 1·67 10·014*x10
-2
* 
Integrated Clusters (IntClust) 
11 
intClust.1 
intClust.2  
intClust.3  
intClust.4  
intClust.5  
intClust.6  
intClust.7  
intClust.8  
intClust.9  
intClust.10 
 
1 
1·47 
0·38 
0·69 
1·58 
1·13 
0·58 
0·65 
1·08 
0·75 
 
 
0·92 
0·24 
0·46 
1·09 
0·70 
0·37 
0·44 
0·72 
0·50 
 
 
2·34 
0·61 
1·03 
2·30 
1·81 
0·93 
0·97 
1·63 
1·13 
<0·0001* 
Hormone therapy 1·23 1·003 1·50 40·047*x10
-2
* 
Chemotherapy 2·02 1·62 2·51 <0·0001* 
Hormone therapy*SPAG5 0·53 0·36 0·77 20·020*x10
-2
* 
Chemotherapy*SPAG5 1·18 0·78 1·78 60·66x10
-1
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E. Multivariable Cox regression analysis of SPAG5 transcript in untreated Lymph 
node negative “Desmedt cohort” 
SPAG5 mRNA (high) 2·34 1·24 4·42 90·0090*x1
0
-3
* 
Oestrogen receptor (positive) 0·67 0·38 1·22 10·19x10
-1
 
NPI 1·74 0·712 4·23 20·22x10
-1
 
Adjuvant-online (AOL) 0·76 0·30 1·94 50·56x10
-1
 
76-gene prognostic signature 
(BeridexVeridex) 
13 
1·52 0·75 3·06 20·24x10
-1
 
F. Multivariable Cox regression analysis of SPAG5 protein for breast cancer-
specific survival at 20 years follow-up in Nottingham historical early stage 
breast cancer cohort (n=1650) 
SPAG5 protein expression (positive) 
1·73 1·23 2·46 20·0020*x1
0
-3
* 
Tumour size (continuous) (mm) 
1·18 1·07 1·31 10·0010*x1
0
-3
* 
Lymph node (LN) status  
Negative  
Positive 
 
1 
1·95 
 
 
1·51 
 
 
2·52 
<0.0001*2·
9x10
-7**
 
Histological grade  
Low/intermediate  
High 
 
1 
1·83 
 
 
1·33 
 
 
2·50 
20·00020*0
x10
-4
* 
Oestrogen receptor (positive) 
1·20 0·82 1·74 30·350x10
-
1
 
HER2 overexpression (positive) 
1·60 1·16 2·52 40·0040*0x
10
-3
* 
Progesterone receptor status (positive) 
0·66 0·47 0·92 10·015*x10
-2
* 
Ki67 (positive) 
1·44 1·03 2·01 30·034 
*x10
-2
* 
Chemotherapy status (CMF) 
1·55 1·13 2·17 10·010*x1
0
-2
* 
Hormone therapy (yes) 
1·31 0·99 1·73 50·059x10
-2
 
Chemotherapy*SPAG5 
1·65 0·85 3·23 10·14x10
-
1
 
Hormone therapy *SPAG5 
1·95 1·14 3·35 10·015*x1
0
-2
* 
G.  Multivariable Cox regression analysis of SPAG5 protein for breast cancer-
specific survival at 10 years follow-up in Nottingham early stage oestrogen 
receptor negative breast cancer cases (n=697) 
Model without interaction terms 
SPAG5 protein expression (positive) 
0·68 0·50 0·92 10·013*x10
-2
* 
Tumour size (continuous) 
1·06 1·02 1·09 10·0010*0
x10
-3
*
 
Lymph node (LN) status  
Negative  
 
1 
 
 
 
 
<0·0001
*
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Positive 2·60 1·92 3·50 
Histological grade  
Low/intermediate  
High 
 
1 
1·67 
 
 
0·98 
 
 
2·86 
50·059x10
-2
 
Menopausal status (post vs pre) 1·34 0·99 1·82 60·060x10
-2
 
HER2 overexpression (positive) 0·92 0·64 1·31 60·64x10
-1 
Bcl2 (positive) 
0·60 0·40 0·90 10·013*x1
0
-2
* 
Chemotherapy status  
 
No Chemotherapy  
CMF  
Anthracycline 
 
 
1 
0·80 
0·61 
 
 
 
0·54 
0·42 
 
 
 
1·18 
0·89 
 
 
 
0·260 
0·010* 
Model with interaction terms 
SPAG5 protein expression (positive) 
0·48 0·30 0·76 20·0020*0x
10
-3
* 
Tumour size (continuous) 
1·05 1·02 1·09 30·0030*0
x10
-3
*
 
Lymph node (LN) status  
Negative  
Positive 
 
1 
2·57 
 
 
1·90 
 
 
3·46 
<0.0001*7
·1x10
-10**
 
Histological grade  
Low/intermediate  
High 
 
1 
1·65 
 
 
0·97 
 
 
2·82 
60·066x10
-2
 
Menopausal status (post vs pre) 
1·35 0·99 1·84 50·056x10
-2
 
HER2 overexpression (positive) 
0·93 0·65 1·34 70·700x10
-1
 
Bcl2 (positive) 
0·63 0·42 0·94 20·023x10
-2
 
Chemotherapy status  
No Chemotherapy  
CMF  
Anthracycline 
 
1 
0·79 
0·59 
 
 
0·54 
0·40 
 
 
1·16 
0·87 
 
 
20·23x10
-1
 
80·008*x1
0
-3
* 
SPAG5*CMF interaction term 0·70 0·32 1·50 30·36x10
-1
 
SPAG5*Anthracycline interaction term 
0·43 0·20 0·93 30·032*x1
0
-2
* 
H. Multivariable Cox regression analysis for clinical outcome (distant relapse-free 
survival (DRFS)) in the University of Texas MD Anderson Cancer Centre 
Taxane/Anthracycline based neo-adjuvant cohort (n=508) 
SPAG5 transcript expression (positive) 
0·68 0·48 0·97 
30·031*x10
-2
* 
Chemo-sensitivity prediction signature 
19 
Low vs high 
 
0·49 
 
0·36 
 
0·67 
<0.000105
·0x10
-6
** 
96- gene genomic grade index (GG1) 
26 
Grade 1/Grade2a vs Grade 2b/Grade 3-like 0·646 0·323 1·29 20·21x10
-1
 
Formatted: Font: Superscript
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Font: Superscript
43 
 
30-gene (DLDA30) 
27 
Low vs High 2·09 0·95 4.56 
60·065x10
-2
 
PAM-50 Molecular subclasses 
28 
PAM50-LumA vs others 
PAM50-LumB vs others 
PAM50-HER2 vs others 
PAM50-Basal-like vs others 
 
0·16 
0·24 
0·14 
0·28 
 
0·04 
0·07 
0·03 
0·07 
 
0·58 
0·88 
0·66 
1·10 
40·042*x10
-2
* 
60·0060* 
0x10
-3
 
30·031*x10
-2
 
10·013*x10
-2
 
60·068x10
-2
 
Clinical AJCC stage  
I/II vs III 
 
2·03 
 
1·38 
 
2·99 
 
40·00040*
0x10
-4* 
MKI67 transcript 1·22 0·71 2·07 40·47x10
-1
 
 
*Statistically significant at p<0·05. 
**Age was a continuous value with increments of 5 years. 
SPAG5; Sperm-associated antigen, ER; Oestrogen receptor; HER2; Human 
epidermal growth factor receptor 2, Bcl2;  B-cell CLL/lymphoma 2; GG;I genomic 
grade index, IntClust; Integrated Clusters; DLDA: diagonal linear discrimination 
analysis, AJCC; American Joint Committee of Cancer.   
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Table-2: Multivariable logistic regression models analysis for pathological complete 
response (pCR) or residual cancer burden (RCB) in neo-adjuvant.  
 
A. Multivariable logistic regression models analysis for pathological 
complete response (pCR) in the Nottingham anthracycline-based neo-
adjuvant BC cohort (SPAG5 protein expression) 
Variables OR 
95.0% CI 
P value 
Lower Upper 
SPAG5 protein expression (+)(high) 8·75 2·42 31·62 
10·0010x10
-3* 
Ki67 protein expression (+)(high) 2·81 0·77 10·24 10·11x10
-1 
Bcl2 protein expression (+)(positive) 
0·19 0.05 0·69 
10·010x10-
2* 
TOP2A protein expression 
(+)(overexpression) 
3·81 0·98 14·73 50·053x10
-2 
ER protein expression (+)(positive) 0·77 0·42 2·84 20·25x10
-1 
HER2 expression (+)(overexpression) 0·84 0·23 3·12 70·79x10
-1 
Taxane (+)(yes) 0·67 0·21 2·21 50·52x10
-1 
Age (continuous)** 
1·04 0·98 1·10 20·25x10
-1 
AJCC stage (i/II us III/IV) 0.35 0·109 1·52 80·084x10
-2 
Histological Grade (G1/2 vs G3) 0·417 0·11 1·54 10·18x10
-1 
B. Multivariable logistic regression models analysis for pathological 
complete response (pCR) in the University of Texas MD Anderson 
Cancer Centre Taxane/Anthracycline-based neo-adjuvant cohort 
SPAG5 transcript) (+)(high) 1·71  1·07 2·74 
20·024x10
-2* 
Pathological Complete response 
(pCR) prediction signature  
Low vs high 
 
 
1·17 
 
 
0·44 
 
 
3·10 
70·75x10-1 
96- gene genomic grade index (GG1) 
26 
Grade 1/Grade2 a vs Grade 2 b/Grade 
3-like 
0·26 0·09 0·78 
10·016x10
-2* 
30-gene (DLDA30) 27 
Low vs High 
1·17 0·44 3·10 70·75x10
-1 
PAM-50 Molecular subclasses 28 
PAM50-LumA vs others 
PAM50-LumB vs others 
PAM50-HER2 vs others 
PAM50-Basal-like vs o 
 
0·16 
0·24 
0·14 
0·28 
 
0·04 
0·07 
0·03 
0·07 
 
0·58 
0·88 
0·66 
1·10 
40·042x10-
2* 
60·0060x10
-3* 
30·031 
*
x10
-2 
10·013 
*
x10
-2 
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60·068x10-2 
Clinical AJCC stage I/II vs III 0.31 0.76 0·45 
10·012* 
Histological grade G1/G2 vs G3 2·37 1·15 4·89 
20·020x10
-2* 
Age of patients (continuous) 0·99 0·96 1·01 20·26x10
-1 
Oestrogen receptor status 
(+)(positive) 
0·46 0·21 1·04 
60·063x10
-2 
Progesterone receptor  (+)(positive) 1·09 0·86 1·39 40·47x10
-1 
C. Multivariable logistic regression models analysis for residual cancer 
burden (RCB) in neo-adjuvant cohorts in Multicentre phase II neo-
adjuvant clinical trial cohort (NCT00455533; n=253) 
SPAG5 transcript) (+)(high) 1·80  1·02 3·02 
40·044x10
-2* 
Oestrogen receptor status 
(+)(positive) 
0·59 0·25 1·36 20·21x10
-1 
Progesterone receptor  (+)(positive) 0·41 0·02 1·02 
40·042x10
-2* 
HER2 (+)(overexpression) 0·96 0·36 2·62 90·94x10
-1 
Age (≥50 years) 0·40  0·22 0·73 
30·0030x1
0
-3* 
Size( ≥5cm) 0·59  0·32 1·09 
90·090x10
-2 
 
*Statistically significant at p<0.·05 
**Age was a continuous value with increments of 1 years. 
 
SPAG5; Sperm-associated antigen, ER; Oestrogen receptor; HER2; Human 
epidermal growth factor receptor 2, TOP2A; Topoisomerase II alpha, Bcl2;  B-cell 
CLL/lymphoma 2; GG;I genomic grade index, IntClust; Integrated Clusters; DLDA: 
diagonal linear discrimination analysis, AJCC; American Joint Committee of Cancer 
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Figure legends 
Figure 1: Concept diagram presenting each of the patient cohorts along with a 
summary of the hypotheses and methodology applied to each.  
Figure 2 (A-F): Clinical outcome of SPAG5-gene-gain/amplification and 
transcript in the METABRIC cohort. Kaplan-Meier curves showing the relationship 
between SPAG5-gene-gain/amplification and breast cancer-specific survival (BCSS) 
in all patients (A), oestrogen receptor positive (ER-positive) (B), and ER- negative 
subgroups (C). Kaplan-Meier curves showing the relationship between SPAG5-
transcript expression and BCSS in all patients (D), oestrogen receptor positive (ER-
positive) (E), ER- negative (F). (G-I): Relationship between SPAG5 transcript 
expression and clinical outcome in untreated lymph node negative breast cancer 
(BC) cohorts.  Kaplan-Meier curves showing the relationship between SPAG5-
transcript expression and: relapse in Wang et al cohort (G), distant relapse in 
Schmidt et al (H), and death from BC in Desmedt et al cohort (I). See text for details.   
(Homo; loss of both gene alleles, hetero; loss of one copy of the gene), Neu; 2 
copies of the gene, Gain; >2 copies of the gene but <6 copies and Amp; 
amplification ≥6 copy of the gene)    
Figure 3 (A-C): Relationship between SPAG5-protein expression and clinical 
outcome in a large, well-characterized cohort of Nottingham Historical Early 
Stage BC cohort (n=1650). Kaplan-Meier curves showing the relationship between 
SPAG5-protein expression and breast cancer-specific survival (BCSS) in all patients 
(G), oestrogen receptor positive (ER-positive) (H) and ER- negative subgroups.   
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Figure 3 (D-F): Clinical outcome of ER-negative breast cancer stratified 
according to SPAG5-protein expression and adjuvant chemotherapy treatment 
status. Kaplan-Meier curves showing the relationship between SPAG5-protein 
expression and breast cancer specific survival (BCSS) in all ER-negative cohort 
cases (D).  E-F: Kaplan-Meier curves showing the relationship between the adjuvant 
chemotherapy protocols (no chemotherapy (No-CT), CMF (cyclophosphamide, 
Methotrexate and 5-Flourouracil) and anthracycline combination therapy) and BCSS 
in low SPAG5-protein expression (-) (E), and high SPAG5-protein expression (+) (F). 
See text for details.  
Supplementary figure legends: 
Supplementary-Fig.S1: Concept diagram summarizing the artificial neural network 
analysis methodology. 
Supplementary-Fig.S2 (A-B): Representative photomicrographs showing 
Spag5SPAG5-protein expression in breast cancer tissue. (A) lowLow 
Spag5SPAG5-protein expression (-) and (B) high Spag5-protein expression (+) in 
neoplastic cells (magnification x 200).  
Supplementary-Fig.S3 (A-B): Gene interaction maps. Visualization of the top 100 
interactions of the common proliferation genes in the Nottingham discovery cohort, 
showing SPAG5 as a central hub (Cystoscope software). (A) and the interaction map 
of proliferation related factor KIF2C (B) where SPAG5 again holds a prominent 
position. 
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Supplementary-Fig.S4: Gene interaction maps. Visualization of the interaction 
map of proliferation related factor KIF2C where SPAG5 again holds a prominent 
position (Cystoscope software). 
Supplementary-Fig.4 5 (A-F):  SPAG5-gene copy number aberrations (CNA), as 
determined by SNP analysis in the METABRIC cohort. The SPAG5-gene-CNA in 
different histological grades (A), PAM50 molecular breast cancer subtypes: Basal-
like (Basal), HER2-enrich (HER2+), luminal A (LumA), Luminal B (LumB) and normal 
breast like (Normal). (B). Box-and-Whisker plots demonstrating the correlation 
between SPAG5 transcript expression and both its CNA (C), ER expression (D), 
molecular subclasses (E), and grade (F). (G-H): The relationship between 
integrative-clusters (Int-Clust1-10) and SPAG5 CNAs (G) and transcript (H). 
Supplementary-Fig.5 6 (A-F): Clinical outcome of SPAG5 transcript and protein 
in the METABRIC and Nottingham historical early stage breast cancer cohorts; 
respectively. Kaplan-Meier curves showing the relationship between SPAG5-
transcript and breast cancer-specific survival (BCSS) in low risk BC [Nottingham 
Prognostic index (NPI)<3·4] (A), lymph node negative (B), and lymph node positive 
(C) subgroups.  Kaplan-Meier curves showing the relationship between SPAG5-
protein expression and breast cancer-specific survival (BCSS) in low risk BC 
[Nottingham Prognostic index (NPI)<3·4] (D), lymph node negative (E), and lymph 
node positive (F) subgroups. 
Supplementary-Fig.6 7 (A-E): Relationship between SPAG5 transcript levels 
and clinical outcome in the combined multicentre cohort (MCC, n=5439). The 
forest plot showing the impact of SPAG5 transcript on survival in terms of hazard 
ratio (HR) and a confidence interval (CI) in different cohorts all at once provides a 
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better (visual) insight into the variability of results between studies (A). Kaplan-Meier 
curves showing the relationship between SPAG5-transcript expression and the risk 
of relapse or death from breast cancer in oestrogen receptor positive (ER-positive) 
(B), ER- negative subgroups (C), lymph node negative (D), and lymph node positive 
(E).  
Supplementary-Fig.8 (A-C): Clinical outcome of SPAG5 protein in the 
Nottingham historical early stage breast cancer cohort. Kaplan-Meier curves 
showing the relationship between SPAG5-transcript and breast cancer-specific 
survival (BCSS) in low risk BC [Nottingham Prognostic index (NPI)<3·4] (A), lymph 
node negative (B), and lymph node positive (C) subgroups.   
Supplementary-Fig.7 9 (A-E): Clinical outcome of Nottingham early stage ER-
negative breast cancer stratified according to SPAG5-protein expression and 
adjuvant chemotherapy treatment status. Kaplan-Meier curves showing the 
relationship between SPAG5-protein expression and breast cancer specific survival 
(BCSS) in: chemotherapy naïve patients (A), chemotherapy treated cohort (B), 
anthracycline naïve patients (C), and anthracycline treated cohort (D).   
Supplementary-Fig.8 10 (A-E): The relationships between SPAG5-protein and 
SPAG5-transcript expression and pathological complete response (pCR) rate 
and clinical outcome following anthracycline combined neo-adjuvant 
chemotherapy (AC-Neo-ACT) treatment with or without taxane.  Relationship 
between SPAG5-protein expression and pCR rate in the Nottingham Anthracycline-
based neo-adjuvant BC cohort (A). Kaplan-Meier curves illustrating the relationship 
between the expression of SPAG5-protein expression in core biopsies prior to 
chemotherapy (B) and in surgically removed residual tumour after chemotherapy, 
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with breast cancer specific survival (BCSS) (C), see text for details.  (D-E): Kaplan-
Meier curves illustrating the relationship between the expression level of SPAG5-
transcript and distant relapse free survival (DRFS), in all cases (D) and in non-
pathological response cases with residual disease (E).  
 
 
 
 
